Official title:  A Phase II trial of Stereotactic Body Radiation Therapy In 
combination with nivolumab plus ipi[INVESTIGATOR_114518]: [STUDY_ID_REMOVED]  
Document date: version 2.0 Date June 27, 2016  
 
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  1 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 1 of 99   (BMS CA209- 444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in writing by 
[CONTACT_4530].  
 
 
 
A PHASE II TRIAL OF STEREOTACTIC BODY RADIATION THERAPY 
IN COMBINATION WITH NIVOLUMAB PLUS IPI[INVESTIGATOR_114519] L CELL CANCER  
UT Southwestern Medical Center  
Johns Hopkins Protocol #:  J15233, IRB00086834  
BMS Protocol #:  CA209 -444 
IND Number:  IND 129041 
IND Sponsor -Investigator: Hans J. Hammers, MD, PhD  
 
Lead Site Principal Investigator:  [INVESTIGATOR_114520] J. Hammers , MD, PhD.  
UT Southwestern Medical Center  
Simmons Comp rehensive Cancer  Center  
[ADDRESS_128067].  
Dallas, TX [ZIP_CODE]  
Phone: [PHONE_2592]  
Fax: [PHONE_2593]  
Email: [EMAIL_2253]
 
 Study Sites:  
• UT Southwestern Medical Center  
Simmons Comprehensive Cancer Center  
(Site-PI: [INVESTIGATOR_114521], M .D., Ph.D.) 
 
• Johns Hopkins University   
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins   SKCCC  
   (Site -PI: [INVESTIGATOR_114522], M.D. ) 
 Co-Investigator/Protocol Authors: Hans Hammers, M.D., Ph.D.  
Danny Song, M.D.  
Rosa Nadal M.D.  
 Biostatistician :    Chul Ahn, PhD.   
      
      
Study Coordinator:     Renee Davis, RN                                              
 Email:  [EMAIL_2254]                                              
 Phone:  [PHONE_2594]    
 
 
 
 
Protocol version  2.0  Date   June 27, 2016  
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  2 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 2 of 99   (BMS CA209- 444) V.  V6.[ADDRESS_128068] or Ethics Committee. By [CONTACT_11217], you agree that the information contained herein will not be disclosed to others without written authorization from the lead site/sponsor, 
except to the extent necessary to initiate the study or conduct study- related activities.  
 
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
   
 
  
 
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  3 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 3 of 99   (BMS CA209- 444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in writing by 
[CONTACT_4530].  
 
 
 
 
INVESTIGATOR’S APPROVAL OF PROTOCOL  
Title : A Phase II , Single Arm Trial, Combining Nivolumab Plus Ipi[INVESTIGATOR_114523]:        _____________________________________  
Principal In vestigator Print:              _____________________________________  
Date:                           ______________________________________  
 
 
 
  
 
  
 
  
 
  
 
  
 
  
 
   
 
 
SYNOPSIS 
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  4 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 4 of 99   (BMS CA209- 444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in writing by 
[CONTACT_4530].  
 
Protocol Title:  A Phase II, Single Arm Trial, Combining Nivolumab Plus Ipi[INVESTIGATOR_114524](s), Dose and Mode of Administration, Duration of Treatment 
with Investigational Product(s):  
For Nivolumab and Ipi[INVESTIGATOR_125]:   
- There will be an induction period (12 WEEKS) cons isting of up to 4 doses  of 
nivolumab plus ipi[INVESTIGATOR_114525] 3 weeks x4 as tolerated, followed by 
[CONTACT_114614]. A treatment cycle during maintenance is 
defined as 6 weeks  
- Nivolumab will be administered IV over 60 minutes at 3 mg/kg combined with 
ipi[INVESTIGATOR_114526] 30 minutes at 1 mg/kg every 3 weeks for 4 doses followed by [CONTACT_114615] 60 minutes at 480 mg  every 4 
weeks  up to 2 years  
For Stereotactic Body Radiation Therapy  (SBRT) :  
- [ADDRESS_128069] 3 weeks after the initiation of nivolumab and ipi[INVESTIGATOR_125]  (SBRT is 
preferred to be delivered in the first 2 weeks)  
 
Study Phase:  This is single -arm Phase II  study in subjects with naïve or pre- treated mRCC  
 
Research Hypothesis:  Nivolumab plus ipi[INVESTIGATOR_114527] (with respect to nivolumab plus ipi[INVESTIGATOR_114528]) in subjects with mRCC  
 
Objective(s):  
Primary Endpoints 
- To assess the overall safety and tolerability of nivolumab plus ipi[INVESTIGATOR_114529].  
- To estimate  the objective response rate (ORR) of this regimen and compare it to 
the reported data on the antitumor activity with the combination o f nivolumab with 
ipi[INVESTIGATOR_114530] m RCC. 
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  5 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 5 of 99   (BMS CA209- 444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in writing by 
[CONTACT_4530].  
 
Secondary  Endpoints: 
 Clinical Endpoints  
- To evaluate time to progression  (TTP) [defined as time between date of registration 
and date of documented progression] and duration of response (DOR) [ defined as 
the time between the date of first response and the date of disease progression or 
death, whichever occurs first. ]. 
- To evaluate progression free survival  (PFS) and overall survival  (OS) 
- To evaluate the local control  of irradiated lesion  
 
 Exploratory Correlative studies:   
- To evaluate potential immune related biomarkers of nivolumab plus ipi[INVESTIGATOR_114531]  6 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 6 of 99   (BMS CA209- 444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in writing by 
[CONTACT_4530].  
 
Contents  
1 INTRODUCTION AND STUDY RATIONALE  ...................................................................................... 11 
1.1 Renal Cell Carcinoma (RCC): Background and Standard Treatments  ........................................ 11 
1.2 Nivolumab in Renal Cell Carcinoma  ........................................................................................... 13 
1.3 Ipi[INVESTIGATOR_114532]  .......................................................................................... 13 
1.4Nivolumab Combined with Ipi[INVESTIGATOR_114532]  ............................................... 14 
1.5 Stereotactic Body Radiation Therapy in Renal Cell Carcinoma  ................................................... 16 
1.6 Rationale to Support Tri al Design  ............................................................................................... 17 
1.7 Dosing for the Nivolumab Combination with Ipi[INVESTIGATOR_125]  ......................................................... 19 
1.8 Dosing for the Stereotactic Body Radiation Therapy  .................................................................. 19 
1.9Overall Risk/Benefit Assessment  ................................................................................................ 19 
INVESTIGATIONAL PLAN and PATIENT SELECTION  ............................................................................... 20 
2.1 Study Design  ................................................................................................................................ 20 
Safety Run -in phase  ...................................................................................................................... 20 
Efficacy phase:  .............................................................................................................................. 20 
2.2 Duration  of Study  ....................................................................................................................... 21 
2.3 Study Population  ........................................................................................................................ 21 
2.3..1  Inclusion Criteria  .......................................................................................................... 21 
2.3.2 Exclusion Criteria:  ................................................................................................................ 22 
2.3.3. Age and Reproductive Status  ............................................................................................. 24 
2.4 Follow -up Visits  .......................................................................................................................... 25 
2.5 Survival Follow -up  ...................................................................................................................... 25 
2.6 Subsequent therapy  .................................................................................................................... 26 
2.7 Concomitant Treatments  ............................................................................................................ 26 
2.7.1 Prohibited and/or Restricted Treatments ............................................................................ [ADDRESS_128070] to Follow -Up  ................................................................................................................ 28 
TREATMENT PLAN/THERAPEUTIC INTERVENTION  ............................................................................... 29 
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  7 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 7 of 99   (BMS CA209- 444) V.  V6.[ADDRESS_128071] and Duration of Therapy  ......................................................... 31 
3.3 Stereotactic Body Radiation Therapy  ......................................................................................... 32 
3.3.2  Simulation procedure .................................................................................................... 33 
3.4 Intervention Plan  ........................................................................................................................ 37 
3.4.1 Antiemetic Premedications and Supportive Care Medications  .......................................... 37 
3.4.2 Bisphosphonates  .................................................................................................................. 37 
3.4.3 Dose Delay Criteria for Nivolu mab and Ipi[INVESTIGATOR_125]  ........................................................... 37 
3.4.4 Dose Modifications for Nivolumab and Ipi[INVESTIGATOR_125]  ............................................................ 39 
3.4.5 Criteria to Resume Treatment on Nivolumab and Ipi[INVESTIGATOR_125]  ........................................... 39 
3.4.6 Discontinuation Criteria for Nivolumab and Ipi[INVESTIGATOR_125]  ..................................................... 39 
3.4.7 Treatment of Nivolumab o r Ipi[INVESTIGATOR_125] -Related Infusion Reactions  ................................. 41 
3.5 Treatment Beyond Disease Progression  .................................................................................... 42 
3.6 Treatment Compliance ............................................................................................................... 43 
3.7 Destruction and Return of Study Drug  ....................................................................................... 43 
3.7.1 Destruction of Study Drug  ................................................................................................... 43 
3.7.2 Return of Study Drug  ........................................................................................................... 44 
3.8 Immunotherapy Adverse Event Management  ........................................................................... 44 
3.9 Adverse events associated with Stereotactic Body Radiation Therapy (SBRT):  ......................... 44 
4 ............................................................................................................................................................ 45 
STUDY ASSESSMENTS AND PROCEDURES ............................................................................................. 45 
4.1 Flow Chart/Time and Events Schedule  ....................................................................................... 45 
4.2 Initial Registration  ....................................................................................................................... 47 
4.3 Study Calendar  ............................................................................................................................ 49 
4.4 Safety Assessments / Considerations  ........................................................................................ [ADDRESS_128072]/MRI  ................................................................................................................................. 54 
4.5.2 MRI/CT Brain  ....................................................................................................................... 55 
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  8 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 8 of 99   (BMS CA209- 444) V.  V6.[ADDRESS_128073] overall response  ........................................................................................ 60 
4.6.10 Confirmation Scans  ............................................................................................................ 61 
4.7 Correlatives Studies  ................................................................................................................... 61 
4.7.1 Samples Collection and Banking .......................................................................................... 63 
5 ............................................................................................................................................................ 63 
ADVERSE EVENTS  .................................................................................................................................. 63 
5.1 Definition and Grade  .................................................................................................................. 64 
5.2 Unanticipated Problems: ....................................................................................................... [ADDRESS_128074] that require Expedited Reporting  ........................................... 70 
5.6 Nonserious Adverse Event Collection and Reporting ................................................................. 70 
5.7 Handling of Expedited Safety Reports  ........................................................................................ 70 
5.8 Reporting:  ................................................................................................................................... [ADDRESS_128075] Abnormalities  ................................................................................................. 72 
5.11 Pregnancy  .................................................................................................................................. 72 
5.12 Overdose  ................................................................................................................................... 72 
5.13 Other Safety Considerations  ..................................................................................................... 73 
5.14 Seven Calendar -Day Telephone or Fax Report:  ........................................................................ 73 
5.15 15 Calendar- Day Written Report:  ............................................................................................. 73 
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  9 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 9 of 99   (BMS CA209- 444) V.  V6.[ADDRESS_128076]/Independent Ethics Committee  ..................................................... 76 
6.3 Informed Consent  ...................................................................................................................... 76 
6.4 Multicenter Guidelines  ............................................................................................................... 77 
6.5 Coordinating Center Responsibilities (UTSW)  ............................................................................. [ADDRESS_128077] the study within the guidelines of Good 
Clinical Practice   ............................................................................................................................ 78 
6.6.2  .............................................................................................................................................. 78 
Required  Documentation (for multi -site studies)  ......................................................................... 78 
7 Data Management, Monitoring/Auditing and Reporting Requirements  .......................................... 79 
8 STUDY MANAGEMENT  ....................................................................................................................... 80 
8.1 Adherence to the Protocol  .......................................................................................................... 80 
8.2 Emergency Modifications  ........................................................................................................... 80 
8.3 Other Protocol Deviations/Violations  ......................................................................................... [ADDRESS_128078] Retention  ............................................................................................................................. 86 
11 Obligations of Investigators  ............................................................................................................. 87 
12 REFERENCES  ..................................................................................................................................... 88 
13 APPENDIX 1          INTERNATIONAL METASTATIC RCC DATABASE CONSORTIUM (IMDC) PROGNOSTIC CRITERIA  ......................................................................................................................... 91
 
14 APPENDIX 2   MANAGEMENT ALGORITHMS FOR IMMUNO -ONCOLOGY AGENTS  .......................... 92 
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  1
0 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 10 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in writing by 
[CONTACT_4530].  
 
 
 
STUDY SCHEMA  
 
 
   
   
 
   
 
    
 
  

SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  1
1 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 11 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in writing by 
[CONTACT_4530].  
 
1 INTRODUCTION AND STUDY RATIONALE  
 1.1 Renal Cell Carcinoma (RCC): Background and Standard 
Treatments  
Renal cell carcinoma accounts for ~3% of all cancers in the U.S. This translates to 58,000 
new cases with 13,000 associated deaths .1 Metastatic disease is found in 30% of subjects at 
diagnosis. Close to 90 - 95% of metas tatic disease is of the clear -cell histology.[ADDRESS_128079] commonly used are the Memorial Sloan- Kettering Cancer 
Center (MSKCC) prognostic scoring system and the International Metastatic RCC Database Consortium (IMDC) prognostic scoring. Each of these systems categorizes patients as favorable, intermediate, or poor -risk based on how many adverse prognostic factors are 
present (0: favorable- risk, 1 -2: intermediate risk, 3 or more: poor -risk).
3,4 The six parameters 
of importance for IDMC prognostic score classification are Karnofsky Performance Statu s 
(KPS), time from diagnosis to treatment, hemoglobin value, calcium concentration, absolute 
neutrophil count, and platelet count.4 The three parameters included in the MSKCC prognostic 
score for pre- treated patients are KPS, hemoglobin value and corrected calcium 
concentration.3 With each system, total number of adverse prognostic factors present has 
been shown to correlate with OS. Overall, a pproximately 25% of patients are in the favorable-
risk group, 50% are in the intermediate -risk group, and 25% are in the poor -risk group (mOS: 
~ 9 months  (mo). In an analysis of 1028 patients scored using the IMDC system, median OS 
for favorable, intermediate, and poor -risk patients is 43.2 mo, 22.5 mo, and 7.8 mo, 
respectively.4 
Until 2005, immunotherapy (IL- 2 or IFN α) was the only active treatment for mRCC. IL -2 was 
approved based on a 15% durable response rate.5,[ADDRESS_128080] documented an objective response rate of 6 - 20% and a modest 
improvement in overall survival  (~2.5 mo ).[ADDRESS_128081] subsequently been approved for the treatment of mRCC, few treatment -naïve patients 
(< 5%) still receive IL -2 or IFN α monotherapy. However, due to each of these agents’ limited 
role in clinic, newer targeted agents have largely replaced cytokines in the treatment of advanced or metastatic RCC.  
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  1
2 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 12 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in writing by 
[CONTACT_4530].  
 
The recognition of the importance of hypoxia inducible factor alpha (HIFα ) signaling to the 
pathogenesis of clear -cell RCC led to the development of two new classes of therapeutics to 
manage this disease. Constitutive HIFα  activation leads to the upregulation or activation of 
several proteins including vascular endothelial growth factor (VEGF). VEGF contributes to the 
development and progression of RCC in several ways including stimulati on of tumor 
proliferation and neovasculature formation. Constitutive HIFα  activation or upregulation occurs 
by [CONTACT_114616], VHL, as well as activation of the upstream PI3K/Akt/mTOR signaling pathway.  
In the treatment -naïve setting, three VEGF pathway agents are currently recommended by 
[CONTACT_68015] (NCCN): sunitinib, bevacizumab/IFN α and 
pazopanib.
10,11 Sunitinib and bevacizumab/IFN α showed improvement in median PFS over 
the active comparator IFNα  (11 mo vs 5.9 mo and 10.2 mo vs 5.4 mo, respectively), whereas 
pazopanib showed superior mPFS ov er placebo (11.1 mo vs 2.8 mo).10,[ADDRESS_128082] inhibitors are the following: fatigue (33 - 55%), diarrhea (20 - 53%), nausea (26 - 44%), 
hypertension (17 - 40%), liver function test (LFT) abnormalities (11 - 53%), hand -foot skin 
reaction (0 - 30%), Grade 3 - 4 neutropenia (1 - 11%), Grade 3 - 4 thrombocytopenia (1 - 8%) 
and low incidences of medically  important events such as thrombosis, proteinuria, reversible 
posterior leukoencophalopathy syndrome (RPLS), bleeding, hypothyroidism, and drug- related 
cardiomyopathy.  
Two mTOR inhibitors are appr oved for the treatment of mRCC. Temsirolimus was approved 
for th e treatment of 1st -line MSKCC poor-risk subjects based on the demonstration of 
improved median OS compared to IFN α (10.9 mo vs 7.3 mo).
[ADDRESS_128083] one prior VEGFR TKI therapy (sunitinib or sorafenib) based on 
the demonstration of improvement in m edian PFS as  compared to placebo (4.9 mo vs 1.9 
mo).[ADDRESS_128084] common or clinically important toxicities observed with mTOR 
inhibitors are fatigue (23 - 51%), nausea (15 - 37%), stomatitis (20 - 36%), diarrhea (21 - 27%), 
dyspnea (9 - 28%), pneumonitis (11%), infections (10 - 27%), Grade 3 - 4 anemia (10 - 
20%).12,[ADDRESS_128085] remained interested in novel immunotherapeutic strategies. 
 
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  1
3 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 13 of 99   (BMS CA209 -444) V.  V6.[ADDRESS_128086] amount of data coming from two studies in subjects with mRCC: CA209009 and 
CA209010. In CA209010, [ADDRESS_128087] one prior -anti-angiogenic 
therapy were randomized to receive nivolumab 0.3mg/kg (n=60 ), 2mg/kg  (n=54) and  10mg/kg 
(n=54).14 The m PFS was 2.7 mo, 4.0 mo, and 4.2 mo at 0.3, 2, and 10 mg/kg respectively . 
The ORR ranged from 20 to 22% across dose levels. Median OS was 18.2 mo at 0.3 mg/kg, 
but was not yet reached at the two highest dose levels. CA209009 enrolled a similar population 
to CA209010, but also included 23 subjects with treatment -naive RCC. Among treatment -
naive subjects, all of whom received nivolumab 10 mg/kg every 3 weeks, the ORR was 13% (3/23).
[ADDRESS_128088] safety database for nivolumab monotherapy in mRCC. All 
treated subjects (n = 167) were included in the safety analyses. Drug- related AEs of any grade 
occurred in 74.6%, 66.7%, and 77.8% of subjects treated at 0.3 mg/kg, 2 mg/kg, and 10mg/kg 
respectively. The most common (≥10% in any group) drug -related AEs included fatigue, dry 
skin, rash, pruritus , arthralgia, nausea, diarrhea, decreased appetite, dry mouth, and 
hypersensitivity. Grade 3 drug -related AEs occurred in 5.1%, 16.7%, and 13% of subjects 
treated at 0.3 mg/kg, 2 mg/kg, and 10 mg/kg, respectively. Related Grade [ADDRESS_128089]/ALT increased, and anemia. No drug -
related Grade 4 or Grade 5 events occurred. No dose- toxicity relationship was identified 
except for hypersensitivity/infusion reactions which occurred most frequently in the 10 mg/kg 
treatment group.
14  
 1.3 Ipi[INVESTIGATOR_114533] 2 clinical trial  
MDX010- 11.15 Two sequential cohorts were studied, each with a loading dose of 3 mg/kg 
followed by 3 doses of either 1 mg/kg (group 3- 1; n = 21) or 3 mg/kg (group 3- 3; n = 40). 
Subjects with stable disease (SD)  or partial or complete response were allowed additional 
treatment. In group 3 -1 (n = 21), one subject (5%) had a partial response (PR). In group 3 -3 
(n = 40), 5 subjects (12.5 %) had a PR. Among 14 treatment- naive subjects in group 3 -3, 3 
(21%) had a PR.16  
In the I pi[INVESTIGATOR_114534] 2 clinical trial MDX010- 11, the major t oxicities were 
colitis (all Grade 3 & 4; 14% in group 3 -1, 33% in group3- 3) and hypophisitis (1 grade 3/4, 1 
grade 1/2 in group 3 -3; none in group 3 -1). Most reported adverse events ( AEs) were Grade 
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  1
4 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 14 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in writing by 
[CONTACT_4530].  
 
1/2 (57% in group 3 -1, 35% in group 3- 3) or Grade 3 (38% in group 3- 1, 48 % in group 3 -3). 
There were 6 subjects (15%) with Grade [ADDRESS_128090] common treatment -
related AEs in group 3- 1 (total 81%) and group 3- 3 (total 93%) were diarrhea (38%and 40%, 
respectively) and fatigue (33% and 38%, respectively).[ADDRESS_128091] AEs were manageable with 
appropriate treatment, including high dose corticosteroids and hormone replacement.  
 1.4 Nivolumab Combined with Ipi[INVESTIGATOR_114535] 1 study 
CA209016. Subjects with mRCC (favorable/intermediate MSKCC score; Karnofsky 
performance status ≥ 80%; untreated or any number of prior therapi[INVESTIGATOR_014]) were randomized to 
receive nivolumab 3 mg/kg + ipi[INVESTIGATOR_125] 1 mg/kg (arm N3 + I1) or nivolumab 1 mg/kg + ipi[INVESTIGATOR_125] 3 mg/kg (arm N1 + I3) IV Q3W for 4 doses then nivolumab 3 mg/kg IV Q2W until progression/toxicity. The primary objective was to assess safety/tolerability; secondary 
objective was to assess antitumor activity. Subjects were randomized to N3 + I1 (n = 21) and 
N1 + I3 (n = 23). Most patients  (n = 34; 77%) had prior systemic therapy (N3 + I1: 16; N1 + I3: 
18). The confirmed ORR was 43% (N3 + I1) and 48% (N1 + I3). DOR  was 4.1+ to 42.1+ wks 
(7 of 9 responses ongoing) in N3 + I1, and 12.1+ to 35.1+ wks (9 of 11 responses ongoing) in N1 + I3. Best response of SD  was seen in 5 (24%) pts (N3 + I1) and 8 (35%) pts (N1 + I3). 
Median PFS was 36.6 wks (N3 + I1) and 38.3 wks (N1 + I3); with 11 of 21 events reported for N3 + I1 and 10 of 23 events reported for  N1 + I3.
17 
The safety of nivolumab combined with ipi[INVESTIGATOR_114536] 1 study CA209016.  Treatment -related AEs were seen in 39/44 pts (89%), including 16/21 (76.2%) in 
N3 + I1 and 23/23 (100%) in N1 + I3. Across the N3 + I1 and N 1 + I3 arms, the most common 
(≤ 20%) treatment related AEs of any grade were fatigue (61%), diarrhea (32%), nausea 
(30%), rash (27%), pruritis (25%), ALT increas ed (23%), AST increased (20%), 
hypothyroidism (20%), and asymptomatic  lipase increased (20%). Grade 3– 4 related AEs 
occurred in 19 pts (29%), including 6/21 (29%) at N3 + I1 and 14/23 (61%)  at N1 + I3. The 
most common (≥5%) drug- related Grade 3 -4 events were asymptomatic lipase increased 
(21%), ALT increased (14%), AST increased (7%), diarrhea (9%), fatigue (5%), amylase increased (5%), colitis (5%), lymphocyte count decreased (5%). No grade 3– 4 pneumonitis 
was seen. No treatment -related deaths were reported. Treatment- related AEs (including 
Grade 3 -4), treatment -related AEs leading to discontinuation, and treatment -related SAEs all 
occurred more commonly in subjects in the N1 + I3 arm than in the N3 + I1.
17 
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  1
5 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 15 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in writing by 
[CONTACT_4530].  
 
Per a study amendment, the N3 + I 1 and N1 + I 3 arms were expanded to better evaluate 
safety and efficacy.  Mature efficacy data was presented at ASCO 2015. The confirmed ORR 
was 38.3% (N3 + I1) and 40.4% (N1 + I3). Best response of SD was achieved in 36.2 % of 
patient in both treatment arms. Median DOR was 67.7 weeks (range 4.1+ to 91.1+) in the N3 
+ I1 arm and 81.1 weeks (range 6.1+ to 81.1+) in the N1 + I3 arm. Responses were durable, 
with >60% of patients continuing to experience ongoing response . The PFS rate (95% CI) at 
24 weeks was 54% (39– 68) in the N3 + I1 arm (N = 47) and 68% (52– 79) in the N1 + I3 arm 
(N = 4 7). Median OS was not reached in either the N3 + I1 arm or in the N1 + I 3.[ADDRESS_128092] Overall Response 
 
NIVO3 + IPI1  NIVO1 + IPI3  NIVO3 + IPI3  
N = 47  N =47  N = 6  
Confirmed ORRa, n (%)  
95% CI  18 (38.3)  
24.5– 53.6 19 (40.4)  
26.4– 55.[ADDRESS_128093] overall responseb, n (%)  
Complete response  
Partial response  
Stable disease  
Progressive disease   
4 (8.5)  
14 (29.8)  
17 (36.2)  
10 (21.3)   
1 (2.1)  
18 (38.3)  
17 (36.2)  
7 (14.9)   
0 
0 
5 (83.3)  
1 (16.7)  
aConfirmed response only; bNo unconfirmed complete responses were reported in either arm; unconfirmed partial 
responses were reported in one patient (2.1%) in the NIVO3 + IPI1 arm and in two patients (4.3%) in the NIVO1 + 
IPI3 arm. Best overall response was not determinable in one patient (2.1%) in the NIVO3 + IPI1 arm and in two 
patients (4.3%) in the NIVO1 + IPI3 arm.  
 
Grade 3 –4 related AEs occurred in 36 pts, including 16/47 (34%) at N3  + I1 and 30/47 (63.8 %) 
at N1 + I3. The most common (≥ 20%) drug -related Grade 3 -4 events were lipase increased 
including 6/47 (12.8%) at N3 + I1 and 12/47 (25.5%) at N1 + I3; ALT increased including 2/47 
(4.3%) at N3 + I1 and 9/47 (19.1%) at N1 + I3; AST increased including 2/47 (4.3%) at N3 + I1 and 4/47 (8.5%) at N1 + I3 and diarrhea including 1/47 (2.1%) at N3 + I1 and 7/47 (14.9%) at N1 + I3. Grade 3- 4 colitis was observed in 6/47 (12.8)  at N1 + I3 only. No grade 3– 4 
pneumonitis was seen. No treatment -related deaths were reported. Treatment -related AEs 
(including Grade 3 -4), treatment -related AEs leading to discontinuation, and treatment -related 
SAEs all occurred more commonly in subjects  in the N1 + I3 arm than in the N3 + I1 arm .
[ADDRESS_128094] AEs
a,b 
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  1
6 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 16 of 99   (BMS CA209 -444) V.  V6.[ADDRESS_128095] AEs are ordered by [CONTACT_114617]3 + IPI1 arm.  
 
More recently the Checkmate 214 study data were released confirming the activity of 
nivolumab/ipi[INVESTIGATOR_43861] a 42% response rate in intermediate and poor -risk patients and 
improvement in overall  survival. The combination of Nivolumab plus Ipi[INVESTIGATOR_114537]. 
1.5 Stereot actic Body Radiation Therapy  in Renal Cell 
Carcinoma 
SBRT is an external beam radiation therapy ( RT) method used to very precisely deliver a high 
dose of radiation to an extracranial target within the body, using either single- fraction treatment 
or a hypofractionated regimen.  Although RCC has traditionally been considered radioresistant , 
it is expected that the use of higher dose- per-fraction regimens associated with SBRT may 
improve response rates and local control compared to conventional RT. Tinkle et al ;19 
compared patients who received SBRT with those who received EBRT for either locally recurrent or metastatic RCC . This study  reported that 1- year local control estimate was 88% 
for patients receiving SBRT, compared to 50% for those receiving external beam radiation 
therapy ( EBRT ) (p=0.001 ). In addition, the use of SBRT was the most important independent 
factor predictive of local control on multivariable analysis. A systematic review of SBRT for 
primary RCC found that amongst 10 reports in the literature, local control was 94%, with grade 
1-2 adverse events of 21%.  The most widely employed fractionation regim en was [ADDRESS_128096] been reported in patients receiving combined SBRT and Category, n (%)  NIVO3 + IPI1  NIVO1 + IPI3  NIVO3 + IPI3  
N = 47  N = 47  N = 6  
 All Grade 3/4  All Grade 3/4  All Grade 3/4  
Skin disorder  18 (38.3)  0 24 (51.1)  1 (2.1)  3 (50.0)  0 
GI disorder  11 (23.4)  1 (2.1)  21 (44.7)  11 (23.4)  3 (50.0)  2 (33.3)  
Endocrinopathy  11 (23.4)  1 (2.1)  20 (42.6)  0 5 (83.3)  0 
Hepatic  7 (14.9)  2 (4.3)  15 (31.9)  10 (21.3)  3 (50.0)  0 
Renal disorder  5 (10.6)  1 (2.1)  7 (14.9)  1 (2.1)  2 (33.3)  0 
Infusion reaction  4 (8.5)  0 3 (6.4)  0 1 (16.7)  0 
Pulmonary  2 (4.3)  0 3 (6.4)  0 0 0 
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  1
7 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 17 of 99   (BMS CA209 -444) V.  V6.[ADDRESS_128097] refers to a phenomenon in which local radiotherapy 
is associated with the regression of metastatic cancer at a distance from the irradiated site. This phenomenon has been associated with increase in tumor -specific T- lymphocytes and a 
decrease in myeloid- derived suppressor cells in melanoma patients treated with ipi[INVESTIGATOR_114538].  
In summary, an approach utilizing established doses of fractionated SBRT (5 fractions of 8-10 Gy per fraction depending on site)  which are considered acceptable from a toxicity 
perspective for the given target site and regional normal seems warranted .
27-[ADDRESS_128098] shown that radiation induc es release of damage- associated molecular 
patterns (DAMPs) such as HMGB1, HSP and calreticulin into the extracellular matrix and thereby [CONTACT_114618]- presenting cells (APCs) such as 
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  1
8 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 18 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in writing by 
[CONTACT_4530].  
 
dendritic cells (DCs) for antigen presentation. Subsequently, the APCs migrate to the draining 
lymph nodes for the presentation of the antigens and efficiently pres ent tumor antigens in the 
cell surface MHC molecules to T cells. Then, T cells initiate an adaptive immune response 
resulting in antibody production and the expansion of cytotoxic T cells. These are delivered to both the primary and metastatic tumor sites.  Increased trafficking of CD8+ T cells to both 
irradiated tumor and their draining lymph node has been observed after RT.
[ADDRESS_128099] been reported. For 
example, increase in MHC- I expression which mediates antitumor immunity by [CONTACT_114619] -antigen by [CONTACT_114620]. Induction of death pathways is 
another mechanism by [CONTACT_114621]. Upregulation of the FAS death receptors on the tumor cell surface in response to radiation 
renders tumor cells particularly susceptible to massive CD8+ T cell -mediated cytotoxic 
attack.
[ADDRESS_128100] this hypothesis  and little is know n about this strategy.  
Very recently, preliminary results of a dose escalation Phase I/II trial  of SBRT followed by 
[CONTACT_40105][INVESTIGATOR_114539] (NTC01497808).
34 The 
authors identified tumor regressions in radiated and unirradiated lesions (an abscopal effect) in some of the patients treated with ipi[INVESTIGATOR_114540]. However, the majority of patient did not respond (64%).  Detection of PD -L1 in melanoma cells  from the participants was 
associated with resistance to this regimen. This finding suggests that PD -1 expression in 
tumor cells is a major impediment to antitumor immune response induced by [CONTACT_114622][INVESTIGATOR_125]. 
34 
The same group aimed to reproduce these clinical observations in a melanoma mouse model 
data. They investigated immune- mechanism both of response and resistance between 
radiation and immune checkpoint inhibitors.  Results from mice studies demonstrated that 
while anti -CTLA4 predominantly inhibits T -regulatory cells (Treg cells) and promotes 
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  1
9 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 19 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in writing by 
[CONTACT_4530].  
 
expansion of T cells (thereby [CONTACT_114623]8 T- cell to Treg (CD8/Treg) ratio), radiation 
enhances the diversity of the T -cell receptor (TCR) repertoire of intratumoral T cells. 
Additionally, resistance was due to upregulation of PD -L1 in tumor  cells and was associated 
with T -cell exhaustion that impairs the CD8+/Treg ratio. Based on these preclinical findings, it 
is expected that dual checkpoint blockade of PD -1 and CTLA -4 synergizes  with SBRT and the 
combination induces non-redundant immune mechanism in cancer patients.34  
 
1.7 Dosing for the Nivolumab Combination with Ipi[INVESTIGATOR_114541]209016 demonstrated a level of clinical activity, as measured by [CONTACT_3168], for the 
combination of nivolumab combined with ipi[INVESTIGATOR_114542]. The dosing regimen including nivolumab 3 mg/kg combined with ipi[INVESTIGATOR_125] 1 mg/kg was chosen because it exhibits similar clinica l activity than nivolumab 1 mg/kg combined with ipi[INVESTIGATOR_125] 3 mg/kg along with a more 
favorable safety profile.
17,18  
 1.8 Dosing for the Stereotactic Body Radiation Therapy  
As mention in the section 1.5; an approach utilizing established doses of fractionated SBRT 
(5 fractions  of 8-10 Gy per fraction depending on site) ( which are considered acceptable from 
a toxicity perspective) in combination with immune- checkpoint inhibitors seems reasonable.  
1.9Overall Risk/Benefit Assessment  
The combination of nivolumab and i pi[INVESTIGATOR_114543] -tumor activity (durable 
responses and stable disease) in a Phase [ADDRESS_128101] non- overlappi[INVESTIGATOR_51140];  their combination may be associated with 
increased efficacy that outweighs the potential incremental increase in toxicity in first - or 
second- line mRCC setting. 
We are hopi[INVESTIGATOR_114544].  
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  2
0 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 20 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in writing by 
[CONTACT_4530].  
 
INVESTIGATIONAL PLAN and PATIENT SELECTION  
2.1 Study Design 
This is a multi- institution, single -arm phase II study to determine the safety and efficacy of 
SBRT (up to 2 metastatic sites preferentially lung, mediastinum  or bone in combination of  
nivolumab and  ipi[INVESTIGATOR_114545] (with a clear -cell component and 
at least 1 measurable metastatic lesion that is not being irradiated).  The primary endpoints 
are safety and tolerability as well as ORR of the  combination of nivolumab plus ipi[INVESTIGATOR_114546].   
The study is planned based on a two- stage design that allows early termination for lack of 
efficacy. A safety run -in phase will be included comprising the first [ADDRESS_128102] 6 patients experience Grade 3/4 toxicity  or a lower grade toxicity requiring immune 
suppressive therapy  during the safety run -in observation period ( 6 weeks after completion of 
SBRT ), enrollment will cease and the study will be halted until further safety analysis of the 
combination regimen can be performed. If less than [ADDRESS_128103] 6 patients experience Grade 3/4 toxicities  or require steroids, we will proceed with additional accrual with this 
regimen.  
Toxicity Event:  ≥grade 3 adverse event (CTCAE v  4.0) with an attribution of possible, 
probable, or definite, as well as need for steroids / immunosuppressive therapy  and lower 
grade toxicity  
Efficacy  phase:  
A minimax Simon two- stage design is planned with the maximum sample size of 25 
(including the 6 in the safety run- in phase). A total of [ADDRESS_128104] 
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  2
1 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 21 of 99   (BMS CA209 -444) V.  V6.[ADDRESS_128105] is registered  
1) Signed Written Informed Consent  
• Willing and able to provide informed consent  
 
2) Target Population  
• Histological confirmation of RCC with a clear -cell component  
• Metastatic (AJCC Stage IV) RCC  
• Prior adjuvant or neoadjuvant therapy for localized or locally advanced RCC is allowed 
provided recurrence occurred = or > [ADDRESS_128106] dose of the adjuvant or 
neoadjuvant therapy  
• Any number of prior systemic treatment regimen in the advanced/metastatic setting is 
allowed (cytokine, anti- angiogenic, mTOR inhibitor  or clinical trial) including previously 
untreated patients  
• Karnofsky Performance Status (KPS) of at least 70%  
• Life expectancy of at least 3 months  
• At least  [ADDRESS_128107] 1.1  
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  2
2 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 22 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in writing by 
[CONTACT_4530].  
 
• Archival Formalin -fixed paraffin -embedded (FFPE)  tumor tissue must be available for 
correlative studies (Note: Fine Needle Aspi[INVESTIGATOR_1516] [FNA] and bone metastases samples 
are not  acceptable for submission)  
• Patients with favorable, intermediate and poor risk categories will be eligible for the study. Patients must be categorized according to favorable versus intermediate/poor 
risk status at registration.  International Metastatic RCC Database Consortium 
(IMDC) must be used to determine  prognostic factors ( Appendix 1)  
 
2.3.2 Exclusion Criteria:  
1) Target Disease Exceptions 
• Subjects with previously treated brain or CNS metastases are eligible provided that the subject has recovered from any acute effects of radiotherapy and is not requiring steroids, and any whole brain radiation therapy was completed at least [ADDRESS_128108] 
2 weeks prior to study drug administration.  Liver metastases will not be included as 
part of the radiated lesions to be treated.  
 2) Medical History and Concurrent Diseases  
• Prior treatment with an anti -PD-1, anti -PD-L1, anti -PD-L2, anti -CD137, or anti -CTLA -
4 antibody, or any other antibody or drug specifically targeting T- cell co -stimulation or 
checkpoint pathways . Prior treatment with HD IL -2 is allowed.  
• Any active or recent  history of a known or suspected autoimmune disease or recent 
history of a syndrome that required systemic corticosteroids (> 10 mg daily prednisone equivalent) or immunosuppressive medications except for syndromes which would not be expected to recur in the absence of an external trigger. Subjects with vitiligo or type I diabetes mellitus or residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement are permitted to enroll. Patients with psoriasis not requiring active, systemic treatment are allowed.  
• Any condition requiring systemic treatment with corticosteroids (> 10 mg daily 
prednisone equivalents) or other immunosuppressive medications within [ADDRESS_128109] dose of study drug. Inhaled steroids and adrenal replacement steroid doses up to 10 mg daily prednisone equivalents are permitted in the absence of active 
autoimmune disease  
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  2
3 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 23 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in writing by 
[CONTACT_4530].  
 
• Uncontrolled adrenal insufficiency  
• Requirement for anti- coagulation with Coumadin, low molecular weight heparin and 
anti-thrombin inhibitors will be accepted if anticoagulation has been stable for at least 
4 weeks and no recent history of prior bleeding complications.  
• Prior malignancy active within the previous [ADDRESS_128110]  or low risk Gleason 
6 prostate cancer  
• Known history of testing positive for human immunodeficiency virus (HIV) or known 
acquired immunodeficiency syndrome (AIDS)  
• Any positive test for hepatitis B or hepatitis C virus indicating acute or chronic infection  
• Known medical condition (eg, a condition associated with diarrhea or acute 
diverticulitis) that, in the investigator’s opi[INVESTIGATOR_1649], would increase the risk associated with study participation or study drug administration or interfere with the interpretation of safety results  
• Major s urger y (eg, nephrectomy) less than [ADDRESS_128111] dose of study drug 
• Anti-cancer therapy less than [ADDRESS_128112] dose of study drug 
• Presence of any toxicities attributed to prior anti -cancer therapy, other than alopecia, 
that have not resolved to Grade 1 (NCI CTCAE v4) or baseline before administration of study drug  3) Physical and Laboratory Test Findings  
• Any of the following laboratory test findings:  
- WBC < 2,000/mm
3  
- Neutrophils < 1,500/mm3  
- Platelets < 100,000/mm3  
- AST or ALT > [ADDRESS_128113] (> [ADDRESS_128114] if liver metastases are present)  
- Total Bilirubin > 1.[ADDRESS_128115] (except subjects with Gilbert Syndrome, who can 
have total bilirubin < 3.0 mg/dL)  
- Serum creatinine > 1.5 x upper limit of normal (ULN) or creatinine clearance < 
40 mL/min (measured or calculated by [CONTACT_12021] -Gault formula)  
 
4) Allergies and Adverse Drug Reaction  
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  2
4 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 24 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in writing by 
[CONTACT_4530].  
 
• History of severe hypersensitivity reaction to any monoclonal antibody  or study drug 
components  
 
5) Other Exclusion Criteria  
• Prisoners or subject s who are involuntarily incarcerated  
• Not suitable for SBRT treatment  
• Subjects who are compulsorily detained for treatment of either a psychiatric or physical illness  
 2.3.3. Age and Reproductive Status  
Women of childbearing potential (WOCBP) is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as [ADDRESS_128116] a documented serum follicle stimulating hormone (FSH)  level less than 40 mIU/mL.  
Women of childbearing potential (WOCBP) receiving nivolumab will be instructed to adhere to contraception for a period of [ADDRESS_128117] been calculated using the upper limit of the half-life for nivolumab (25 days) and are based on the p rotocol requirement that WOCBP 
use contraception for 5 half -lives plus 30 days and men who are sexually active with 
WOCBP use contraception for 5 half -lives plus 90 days.  
 
Highly effective methods of contraception include:  
• Male condoms with spermicide 
• Horm onal methods of contraception including combined oral contraceptive pi[INVESTIGATOR_3353], 
vaginal ring, injectables, implants and intrauterine devices (IUDs) such as Mirena 
by [CONTACT_70716]’s WOCBP partner Female partners of male subjects participating in the study may use hormone based contraceptives as one of the acceptable methods of contraception since they will not be receiving study drug 
• Nonhormonal IUDs, such as ParaGard
 
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  2
5 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 25 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in writing by 
[CONTACT_4530].  
 
• Tubal ligation  
• Vasectomy  
• Complete Abstinence*  
*Complete abstinence is defined as complete avoidance of heterosexual intercourse 
and is an acceptable form of contraception for all study drugs. Subjects who choose complete abstinence are not required to use a second method of contraception, but 
female subjects must continue to have pregnancy tests. Acceptable alternate methods 
of highly effective contraception must be discussed in the event that the subject 
chooses to forego complete abstinence.  
 
Less effective methods of contraception include:  
• Diaphragm with spermicide 
• Cervical cap with spermicide 
• Vaginal sponge  
• Male Condom without spermicide  
• Progestin only pi[INVESTIGATOR_114547]’s WOCBP partner  
• Female Condom*.  
*A male and female condom must not be used together  
 
 2.[ADDRESS_128118] three follow -up visits (X1, X2 and X3) are required for all subjects. Visit X1 will take 
place 30 days ( +/- 1 week) after the last dose of study medication in the cycle where nivolumab 
was discontinued, visit X2 will take place 8 weeks ( +/- 1 week) after last dose of nivolumab 
was administered and visit X3 will take place 15 weeks ( +/- 1 week) after last dose of 
nivolumab was administered. The duration of the follow -up period up to the X3 visit is equal 
to approximately [ADDRESS_128119] every 8 weeks ( +/- 1 week) until 
study drug -related toxicity has resolved, stabilized or been deemed irreversible.  
 2.5 Survival Follow -up  
After follow -up visits, study subjects will be contact[CONTACT_457] 3 months for survival data. Other 
potential data such as the subjects’ follow -up treatment or care may be requested during these 
contacts. The contacts can be via telephone or correspond with disease assessment visits, if 
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  2
6 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 26 of 99   (BMS CA209 -444) V.  V6.[ADDRESS_128120] went off treatment for other than progressive disease, or other scheduled visits.  
2.6 Subsequent therapy  
Subjects for whom treatment is discontinued should be treated according to clinical 
circumstances and should be managed at the local  clinician’s discretion.  
 2.7 Concomitant Treatments  
 2.7.1 Prohibited and/or Restricted Treatments  
The following medications are prohibited during the study:  
• Immunosuppressive agents (except to treat a drug -related adverse event). Systemic 
corticosteroids > 10 mg daily prednisone equivalent (except as stated in Section 2.7.3  
below or to treat a drug- related adverse event).  
• Any concurrent antineoplastic therapy (ie, chemotherapy, hormonal therapy, 
immunotherapy, radiation therapy except for palliative radiation therapy surgical 
resection except for palliative surgical resection).  
• Supportive care for disease- related symptoms may be offered to all subjects on the 
trial. 
• Any concurrent meds should be evaluated for being absolutely necessary. Particularly 
drugs with potential liver toxicity should be avoided if possible  
 2.7.2 Other Restrictions and Precautions  
Palliative (limited -field) radiation therapy and palliative surgical resection are permitted, if the 
following criteria are met:  
• The subject will be considered to have progressed at the time of palliative therapy and must meet criteria to continue with treatment  beyond progression. ( Section 3.5 )  
 2.7.3 Permitted Therapy  
Subjects are permitted to use topi[INVESTIGATOR_2855], ocular, intra -articular, intranasal, and i nhalational 
corticosteroids (with minimal systemic absorption). Physiologic replacement doses of systemic corticosteroids are permitted, up to 10 mg/day prednisone equivalents. A brief course 
of corticosteroids for prophylaxis (eg, contrast dye allergy) or  for treatment of non -autoimmune 
conditions (eg, delayed- type hypersensitivity reaction caused by [CONTACT_13132]) is permitted.  
Concomitant medications are recorded at baseline and throughout the treatment phase of the study in the appropriate section o f the case report form (CRF). All medications (prescriptions 
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  2
7 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 27 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in writing by 
[CONTACT_4530].  
 
or over the counter medications) continued at the start of the study or started during the study 
and different from the study drug must be documented in the concomitant therapy section of 
the CRF .  
 2.[ADDRESS_128121] (and non- investigational product at the 
discretion of the investigator) for any of the following reasons:  
• Subject’s request to stop study treatment  
• Any clinical adverse event, laboratory abnormality or intercurrent illness which, in the 
opi[INVESTIGATOR_871], indicates that continued participation in the study is not in 
the best interest of the subject  
• Protocol defined disease progression (subjects may be permitted to continue treatment 
beyond initial disease progression see Section 3.5 )  
• Loss of ability to freely provide consent through imprisonment or involuntarily incarceration for treatment of either a psychiatric or physical (eg, infectious disease) illness  
• Additional protocol specified reasons for discontinuation (see Section 3.4.5 )  
In the case of pregnancy, the study  subject  will be permanently discontinued in an appropriate 
manner. All subjects who discontinue study drug should comply with protocol specified follow -
up procedures as outlined in Section 3 (Study Assessment  and Procedures) . The only 
exception to this requirement is when a subject withdraws consent for all study procedur es 
including post -treatment study follow -up or loses the ability to consent freely (ie, is imprisoned 
or involuntarily incarcerated for the treatment of either a psychiatric or physical illness).  
If study drug is discontinued prior to the subject’s completion of the study, the reason for the discontinuation must be documented in the subject’s medical records and entered on the appropriate CRF page.  
 
 2.[ADDRESS_128122] continue to be followed for collection of outcome 
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  2
8 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 28 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in writing by 
[CONTACT_4530].  
 
and/or survival follow -up data as required and in line with Section 3 (Study Assessment and 
Procedures) until death or the conclusion of the study.  
 2.9.[ADDRESS_128123] with him/her or persons previously authorized by [CONTACT_20439]. Subjects should notify the 
investigator of the decision to withdraw consent from future follow -up in writing , whenever 
possible. The withdrawal of consent should be explained in detail in the medical records by 
[CONTACT_093], as to whether the withdrawal is from further treatment with study drug only or 
also from study procedures and/or post treatment study follow -up, and entered on the 
appropriate CRF page. In the event that  vital status (whether the subject is alive or dead) is 
being measured, publicly available information should be used to determine vital status only 
as appropriately directed in accordance with local law.  
 2.9.[ADDRESS_128124]’s medical records. If it is determined that the subject has died, the site will use permissible local methods to obtain the date and cause of death.  
The site staff and representative will consult publicly available sources, such as public health registries and databases, in order to obtain updated contact [CONTACT_3031]. If after all attempts, the subject remains lost to follow -up, then the last known alive date as determined by [CONTACT_74087]’s medical records.  
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  2
9 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 29 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in writing by 
[CONTACT_4530].  
 
 
TREATMENT PLAN/THERAPEUTIC INTERVENTION 
 3.1 Treatment Plan  
 3.1.1 Study Drug  
Study drug includes  both Investigational (Investigational Medicinal Product)  and Non -
Investigational Therapy and can consist of the following:  
• All products, active or placebo, being tested or used as a comparator in a clinical 
trial 
• Study required premedication, and other drugs administered as part of the study 
that are critical to claims of efficacy (eg, background therapy, rescue medications)  
•  Diagnostic agents: (such as glucose for glucose challenge) given as part of the 
protocol requirements must also be included in the dosing data collection  
Nivolumab 100 mg (10 mg/mL) will be packaged in an open -label fashion. Five or t en 
nivolumab [ADDRESS_128125]  form and submit the form to BMS to 
receive the medication and obtain re- supply.   
Ipi[INVESTIGATOR_114548] a sterile, preservative- free solution in 40 mL vials at a 
concentration of 5 mg/mL. Each vial contains a concentrated solution with the equivalent of 
[ADDRESS_128126] Description: Treatment Period 
 
 
 

SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  3
0 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 30 of 99   (BMS CA209 -444) V.  V6.[ADDRESS_128127]  (IMP)  in some 
regions, is defined as pharmaceutical form of an active substance or placebo being tested or 
used as a reference in a clinical study, including products already with a marketing 
authorization but used or assembled (formulated or packaged) differently than the authorized form, o r used for an unauthorized indication, or when used to gain further information about 
the authorized form.  The investigational product should be stored in a secure area according to local regulations. It is the responsibility of the investigator to ensure that investigational product is only 
dispensed to study subjects. The investigational product must be dispensed only from official 
study sites by [CONTACT_20443].  
In this protocol, investigational products are: 
• Nivolum ab (BMS -936558) 
• Ipi[INVESTIGATOR_125]  
 
 3.1.[ADDRESS_128128](s) is/are: medications used to treat nivolumab or 
ipi[INVESTIGATOR_114549] -related reactions (eg, steroids, anti -emetics); these non- investigational 
products should be sourced by [CONTACT_114624].  
 3.1.[ADDRESS_128129] storage manager should ensure that the study drug is stored in accordance with 
the environmental conditions (temperature, light, and humidity) as determined by [CONTACT_20444]. If concerns regarding the quality or appearance of the study drug arise, the st udy drug should 
not be dispensed and contact [CONTACT_114625] [INVESTIGATOR_97318].   
If stored in a glass front refrigerator, vials should be stored in the carton. Recommended safety measures for preparation and handling of nivolumab and ipi[INVESTIGATOR_114550].  
Investigational product documentation must be maintained that includes all processes 
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  3
1 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 31 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in writing by 
[CONTACT_4530].  
 
required to ensure drug is accurately administered. This includes documentation of drug 
storage, administration and, as applicable, storage temperatures, reconstitution, and use of 
required processes (eg, required diluents, administration sets).  
Infusion- related supplies (eg, IV bags, in- line filters, 0.9% NaCl solution) should be purchased 
locally if permitted by [CONTACT_54019].  
For nivolumab and ipi[INVESTIGATOR_125], please refer to the current version of the Investigator 
Brochures and/or pharmacy reference sheets for complete storage, handling, dispensing, and infusion information.  
 Nivolumab is to be administered as an approximately 60- minute IV infusion. At the end of the 
infusion, flush the line with a sufficient quantity of normal saline.  
Ipi[INVESTIGATOR_114551] 30- minute IV infusion. At the end of the 
infusion, flush the line with a sufficient quantity of normal saline or 5% dextrose solution.  
When both study drugs are to be administered on the same day, separate infusion bags and filters must be used for each infusion. Nivolumab is to be administered first.  
3.[ADDRESS_128130] and Duration of Therapy  
Table 4. Schedule for SBRT  
SBRT is to be delivered anytime between Day 1 of Week 1 and Day 1 of Week 4 of the 
NIVO/IPI [INVESTIGATOR_114552] 1  D1 Week 2  Week 3  Week 4  D1 Week 5  Week 6  
 
SBRT   
5 fractions of 10 Gy    
 
 
Table 5 . Dosing Schedule for Cycle 1 and Cycle 2  
1 cycle = 6 weeks  
 Week 1  Week 2  Week 3  Week 4  Week 5  Week 6  
 
Nivolumab 3 
mg/kg IV + 
Ipi[INVESTIGATOR_125] 
1 mg/Kg IV  Day 1  
Nivolumab 3 
mg/kg IV + 
Ipi[INVESTIGATOR_125] 
1 mg/Kg IV    Day 1  
Nivolumab 3 
mg/kg IV + 
Ipi[INVESTIGATOR_125] 
1 mg/Kg IV    
 
 
Table 6. Dosing Schedule for Cycle 3 and Beyond (up to 2 years) every 4 weeks  
1 cycle = 8 weeks  
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  3
2 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 32 of 99   (BMS CA209 -444) V.  V6.[ADDRESS_128131]  30 minutes after 
completion of the nivolumab infusion.  
Ipi[INVESTIGATOR_102323] 0.9% Sodium Chloride Solution or 5% Dextrose solution. Nivolumab may be diluted in 0.9% Sodium Chloride Solution or 5% Dextrose solution.  
The dosing calculations should be based on the actual body weight. If the subject’s weight on 
the day of dosing differs by > 10% from the weight used to calculate the dose, the dose must be recalculated. (The weight used to calculate the dose should always  be the most recently 
recorded weight). All doses should be rounded to the nearest milligram. There will be no dose modifications allowed.  During cycles [ADDRESS_128132]’s medical record and CRF.  
Maintenance nivolumab will be allowed up to [ADDRESS_128133]. Danny Song  (JHU), 
[CONTACT_114661] (UTSW)  or co -investigator Radiation Oncologist from the Radiation 
Therapy Department  to determine eligibility/feasibility for SBRT. The cancer lesion(s) to be 
radiated should be determined by [CONTACT_114626]/Medical Oncologist using the criteria stated below . 
 
3.3.[ADDRESS_128134] common sites of involvement with metastatic RCC are lung (45%), bone (29%), 
lymph node (22%), liver (20%), and adrenal (9%)
1.  Dosing, patient setup/immobilization, and 
dose constraints for lung sites will be in accordance with established experience specific to 
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  3
3 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 33 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in writing by 
[CONTACT_4530].  
 
those sites.  Bone and lymph node sites will be treated and dosed in accordance with their 
anatomic location (extremity, thorax, or abdomen/pelvis) and surrounding dose- sensitive 
structures.  The gross target volume (GTV) for SBRT will be a minimum of 1cm in short -axis 
diameter (in order to help assure an adequate volume of  tumor cells for immune stimulation), 
and a maximum of 5cm in long -axis diameter.  Liver lesions will not be considered for SBRT 
for patients on the protocol, as this could potentially lead to higher rates of liver failure and/or autoimmune hepatitis in the setting of concomitant immunotherapy.  
Five fractions of SBRT at [ADDRESS_128135] 3 weeks after the 
initiation of nivolumab and ipi[INVESTIGATOR_125].  Given the parallel goals of radiation of enhancing antitumor immune response and stimulating auto -vaccination (rather than to treat all known 
tumor tissue), as well as maintaining consistency in target dose prescription for purposes of 
analysis, the planning target volume and treatment margins may be defined in a manner which 
may i nvolve potentially less than complete prescription dose coverage of the involved tumor.  
A working hypothesis of the trial is that optimal immune stimulation will occur with an ablative dose of radiation; the most robust dose -response relationships for SBRT come from the lung 
SBRT experience, where a biologically equivalent dose (BED) of approximately 100 Gy (equivalent to 10 Gy x 5 fractions) has been shown to be a threshold dose for optimal local control
2,3 
If all relevant normal tissue constraints cannot be met while treating the entire metastatic focus, then planned target volume ( PTV) margins will be modified downward in an iterative 
process to a minimum of 0mm (from GTV) in order to achieve normal tissue constraints. If normal tissue constraints still cannot be met, then consideration will be given to treating another lesion if a suitable alternative exists.  If no suitable alternative target exists, then an 
nPTV  will be generated which impi[INVESTIGATOR_114553], until all protocol -specific SBRT  tissue constraints have been met. For example,  if the 
entire GTV can not be treated with 5 x 10 Gy because of surrounding normal tissue constraints, then only part of the gross target volume can be exposed to 5 x 10 Gy while the surrounding margin receives 5 x 8 Gy.  Liver lesions will not be considered as a radiated target.   
3.3.2  Simulation procedure  
Patients will undergo simulation and immobilization in accordance with site -specific protocols 
established in the Dept.  of Radiation Oncology.   
Patients being treated to lung/thoracic or abdominal lesions will have respi[INVESTIGATOR_114554] 4D -CT scanning or with Active Breathing Control 
(ABC) and inspi[INVESTIGATOR_114555].  Patients with greater than or equal to 5 mm of breathing 
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  3
4 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 34 of 99   (BMS CA209 -444) V.  V6.[ADDRESS_128136] an Internal Target Volume (ITV) delineated using end- inspi[INVESTIGATOR_114556]-expi[INVESTIGATOR_114557] 4D -CT scan.  A wingbo ard and/or alpha cradle may be utilized 
for patient positioning. Patients who have target volumes in close proximity to the upper GI 
tract (stomach, duodenum, small bowel) shall be instructed to be NPO for [ADDRESS_128137] simulation for patients with targets in the mediastinum.   
Patients being treated to pelvic lesions will be positioned with the Combifix device.  Bladder filling (patient instructed to drink 30 oz. of water prior to simulation) is to be utilized if doing so will help eliminate or minimize small bowel from the treatment field.   
For extremity lesions, immobilization with alpha cradle and/or Vac -Loc bags will be utilized.   
CT simulation will be performed with minimum 3mm slice thickness.  MRI simulation may be utilized if target volume or normal anatomy delineation will be enhanced with its use.  Diagnostic MRI scans may also be utilized to provide complementary anatomic information to CT simulations.  MRI and CT  simulation images will be fused using either Pi[INVESTIGATOR_114558].    
The target volume (PTV or nPTV) for centrally located or mediastinal sites should not directly involve critical structures such as central bronchial tree (within 2cm of carina or hilum,  as 
defined in RTOG 0813), esophagus, great vessels, or brachial plexus.  
 
3.3.3  Target delineation  
Spi[INVESTIGATOR_114559], vertebral body and pedicle, or posterior 
elements only (as defined in NRG- BR-001).  For each of these met astases, GTV delineation 
will include at a minimum the involved vertebral body and both pedicles, or the involved posterior elements and both pedicles.   
Other targets will be delineated primarily based on CT simulation images, using the windowing settings  specific for the anatomic location within which the target is contained.  Additional 
imaging modalities such as MRI may be utilized at the radiation oncologist’s discretion; rigid image registration is recommended if utilizing complementary imaging modalities in addition to CT simulation scans.  
 
3.3.4  Normal tissue delineation and constraints  
The following normal tissue delineation definitions are for purposes of consistency in those 
cases where ambiguity could potentially lead to inter -individual variatio ns in contouring, and 
to adhere to well -defined generally accepted SBRT practice when available.  
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  3
5 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 35 of 99   (BMS CA209 -444) V.  V6.[ADDRESS_128138] 10 below 
the inferior extent of the PTV.  
Cauda equina  is defined as beginning at the conus (usually L1 or L2) and including the entire 
spi[INVESTIGATOR_114560].   
Sacral plexus  will includes the nerve roots beginning at L5 and extending to S3 bilaterally from 
neuroforamina to the coalescing of nerves at the obturator internus.  
Esophagus  is to be defined to include all layers from mucosal to adventitia, starting at least 
10cm cranial and caudal to the extent of PTV.  
Brachial plexus  is to be contoured if target volume (PTV) is within [ADDRESS_128139] (or base) for 
purposes of contouring will begin at the level of the inferior aspect of the aortic arch (i.e. 
aortopulmonary window) and extend inferiorly to the apex of the heart.  
Trachea and proximal bronchial tree  will be defined as two structures; distal 2cm of trachea 
will be included in what is defined as proximal bronchial tree.  Proximal bronchial tree will include the caudal 2cm of distal trachea plus proximal airways bilaterally as defined by [CONTACT_114627]
5 / RTOG 0813.   
Lungs  will be contoured separately as well as combined into a single structure for DVH 
purposes.  GTV and trachea / proximal bronchial tree are to be excluded.  
Skin is to be defined as the outer 5mm of body surface.  
Great vessels (aorta, vena cava) will be contoured including entire thickness to the adventitia.  Contours should extend from 10cm caudal to 10cm cranial from extent of PTV.  
Duodenum  will be defined from stomach, to where the superior mesenteric artery crosses over 
the 3
rd part of duodenum.  
Small bowel  will be defined from duodenum (see above) to ileocecum.  If small bowel and 
large bowel cannot be delineated with confidence, then the more generous contour should be utilized.  
Large bowel  will b e defined from ileocecum to rectum (including sigmoid). 
Rectum  is to be defined from the peritoneal reflection cranially, typi[INVESTIGATOR_114561] 12- [ADDRESS_128140] at approximat ely level of bottom of 
ischial tuberosities.  
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  3
6 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 36 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in writing by 
[CONTACT_4530].  
 
Renal hilum  will be contoured where renal vessels and renal pelvis are adjacent as they 
enter/exit the kidney.  
Ureter  is to be contoured from 10cm cranial to 10cm caudal to extent of PTV, and terminates 
at renal  hilum and vesicoureteral junction, respectively.  
Bile ducts  are identified by [CONTACT_114628] a surrogate.  
Liver  is entire liver minus GTV.  
Kidneys  will be defined in their entirety, but excluding the pelvis / collecting system.  
Penile bulb is best delineated on MRI images, but can be visualized on CT if MRI unavailable.  
As defined by [CONTACT_114629]6, it is to be contoured as the  cranial portion of the corpus 
spongiosum, between the corpora cavernosal and beneath the genitourinary diaphgram.  
 
Normal tissue constraints  
The dose will be prescribed to the minimal isodose line that completely covers the GTV (or 
ITV if applicable) plus  a 0-5 mm margin to create a planning target volume (PTV).  In order to 
achieve normal tissue dose constraints, PTV margins may be utilized which may not encompass the entire target volume with setup uncertainty and anatomic motion; PTV margins may be utilized which are negative (i.e. PTV smaller than GTV volume) in order to achieve protocol -specified doses while respecting normal tissue tolerances; such PTV volumes will be 
termed ‘nPTV’. All relevant adjacent normal structures including but not limited to the heart, 
esophagus, aorta, spi[INVESTIGATOR_1831], kidneys, rectum, bowel, liver, and stomach within 5 cm of the 
GTV will be identified for the purpose of limiting incidental radiation to these structures.  
Dose heterogeneity within the PTV may be high, and within the paradigm of SBRT is considered acceptable without constraints.  The dose to any tissue outside of the PTV should not exceed 5% of the prescription dose.  
 
3.3.5 Treatment  delivery technical factors  
Treatment will be initiated within three weeks of the initial treatment planning simulation study. 
Treatment will be delivered with a minimal inter- fraction interval of 36 hours, and no greater 
than 84 hours between fractions. Only photon (x -ray) beams with energies greater than or equal to 6MV are allowed.  Tumors 
located within the lungs should be treated with energies of no greater than 10MV, except for specific beams where large soft tissue distances must be traversed to reach target.  Dynamic conformal arcs and flattening -filter-free beams are acceptable.   All dose calculations should 
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  3
7 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 37 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in writing by 
[CONTACT_4530].  
 
be performed with tissue heterogeneity corrections. 
Image- guided therapy (IGRT) utilizing on- board cone -beam imaging is required for each 
fraction prior to delivery of treatment.  Patients should be aligned to the visible tar get volume.  
In cases where soft tissue contrast is poor on CBCT imaging, fiducial markers should be utilized for more accurate setup.   
3.4 Intervention Plan  
 3.4.1 Antiemetic Premedications and Supportive Care Medications   
Antiemetic premedications should not be routinely administered prior to dosing of drugs. 
Symptomatic antiemetics  may be administered at the Investigator’s discretion. Palliative and 
supportive care for disease- related symptoms will be offered to all patients on this trial.  
3.4.2 Bisphosphonates  
The use of bisphosphonates (e.g., zoledronic acid) or denosumab is permitted if patient has 
been using them prior to the study for at least 1 month.  
 3.4.3 Dose Delay Criteria for Nivolumab and  Ipi[INVESTIGATOR_114562] -related adverse events (regardless of whether or not the 
event is attributed to nivolumab and ipi[INVESTIGATOR_125]). All study drugs must be delayed until 
treatment can be resumed.  Imaging studies and the collection of blood and tissue for 
correlative studies should continue  as planned  even if dosing is interrupted . Radiation 
treatment should continue if the treatment is unlikely to worsen adverse event.  
Nivolumab and ipi[INVESTIGATOR_114563] f or the following:  
• Any Grade ≥ 2 non -skin, drug -related adverse event, with the following exceptions: 
o Grade 2 drug -related fatigue or laboratory abnormalities do not require a 
treatment delay  
• Any Grade 3 skin, drug- related adverse event  
• Any Grade [ADDRESS_128141], ALT, or total bilirubin:    
o If a subject has a baseline AST, ALT, or total bilirubin that is within normal limits, delay dosing for drug- related Grade ≥ [ADDRESS_128142], ALT, or total bilirubin within the Grade 1 toxicity range, delay dosing for drug -related Grade ≥ 3 toxicity  
• Grade 3 amylase or lipase abnormalities that are not associated with symptoms or clinical manifestations of pancreatitis do not require a dose delay.  
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  3
8 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 38 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in writing by 
[CONTACT_4530].  
 
• Any adverse event, laboratory abnormality, or intercurrent illness which, in the 
judgment of the investigator, warrants delaying the dose of study medication 
 
During cycles [ADDRESS_128143] be delayed at the same time. Following the up to 4 administrations  of the induction combination therapy with NIVO/IPI , Dose 
[ADDRESS_128144] ion therapy. If the 
4th dose of induction therapy has not been administered due to treatment delays  or the 
discontinuation of combination therapy because of primarily ipi[INVESTIGATOR_114564], high grade diarrhea or hepatitis before Day113, that dose/doses  will be omitted 
and maintenance dosing will begin.  
  The schema is noted in Figure 3.4. 2 below.  
 
Figure 3.4.2 Dosing/Treatment Schema for nivolumab/ ipi[INVESTIGATOR_114565] 
* Cycle 1 of maintenance will begin 3 weeks after the 4th dose of induction therapy or after 
Day 113 if the 4th dose of induction therapy has not been administered due to treatment 
delays.  
 
I 
n 
d 
u 
c 
t 
i 
o 
n 
  
 P 
h 
a 
s 
e 
N 
I 
V 
O 
  
 3 
  
 m 
g 
/ 
k 
g 
  
 / 
  
 I 
P 
I 
  
 1 
  
 m 
g 
/ 
k 
g 
( 
g 
i 
v 
e 
n 
  
 e 
v 
e 
r 
y 
  
 3 
  
 w 
e 
e 
k 
s 
  
 u 
p 
  
 t 
o 
  
 4 
  
 d 
o 
s 
e 
s 
) 
M 
a 
i 
n 
t 
e 
n 
a 
n 
c 
e 
  
 P 
h 
a 
s 
e 
N 
i 
v 
o 
l 
u 
m 
a 
b 
  
 M 
o 
n 
o 
t 
h 
e 
r 
a 
p 
y 
3 
  
 m 
g 
/ 
k 
g 
( 
e 
v 
e 
r 
y 
  
 2 
  
 w 
e 
e 
k 
s 
, 
  
 1 
  
 c 
y 
c 
l 
e 
s 
  
 = 
  
 6 
  
 w 
e 
e 
k 
s 
) 
R 
a 
d 
i 
a 
t 
i 
o 
n 
B 
i 
o 
m 
a 
r 
k 
e 
r 
s 
/ 
B 
i 
o 
p 
s 
y 
D 
o 
s 
e 
  
 1 
D 
o 
s 
e 
  
 2 
 D 
o 
s 
e 
  
 3 
 D 
o 
s 
e 
  
 4 
D 
a 
y 
1 
D 
a 
y 
1 
5 
D 
a 
y 
  
 2 
9 
C 
y 
c 
l 
e 
  
 1 
 C 
y 
c 
l 
e 
  
 2 
  
 e 
t 
c 
. 
B 
i 
o 
m 
a 
r 
k 
e 
r 
s 
/ 
B 
i 
o 
p 
s 
y 
P 
r 
o 
g 
r 
e 
s 
s 
i 
o 
n 
Nivolumab Monotherapy 480mg 
(every 4 weeks, 1 cycle = 6 weeks)  
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  3
9 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 39 of 99   (BMS CA209 -444) V.  V6.[ADDRESS_128145] the next scheduled timepoint per protocol, the next scheduled timepoint will be delayed until dosing resumes. If treatment is delayed > [ADDRESS_128146] be permanently discontinued from study therapy, except as specified in discontinuation section.  
Subjects may resume treatment with study drug when the AEs resolve to Grade ≤ 1 or baseline value, with the following exceptions:  
• Subjects may resume treatment in the presence of Grade 2 fatigue  
• Subjects who have not experienced a Grade 3 drug -related skin AE may resume 
treatment in the presence of Grade 2 skin toxicity  
• Subjects with baseline Grade [ADDRESS_128147]/ALT or  total bilirubin who require dose delays for 
reasons other than a 2- grade shift in AST/ALT or AST/ALT or total bilirubin  
• Subjects with combined Grade [ADDRESS_128148]/ALT AND total bilirubin values meeting discontinuation parameters should have treatment permanently discontinued.  
• Drug -related pulmonary toxicity, diarrhea, or colitis, must have resolved to baseline 
before treatment is resumed.  
• Drug -related endocrinopathies adequately controlled with only physiologic hormone 
replacement may resume treatment.  
3.4.6 Discontinuation Criteria for Nivolumab and Ipi[INVESTIGATOR_114566]: 
If treatment is delayed > [ADDRESS_128149] with a dosing interruption lasting > 6 
weeks, the overall PI ([CONTACT_114662]) must be consulted. Tumor assessments should conti nue as per protocol even if dosing is interrupted. 
Dosing interruptions > [ADDRESS_128150] with a dosing 
interruption lasting > [ADDRESS_128151] be consulted. Tumor assessments  and 
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  4
0 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 40 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in writing by 
[CONTACT_4530].  
 
the collection of blood and tissue samples for correlati ve studies should continue as per 
protocol even if dosing is interrupted . Radiation treatment should continue if the treatment is 
unlike ly to worsen the adverse event.  
• Any Grade 2 drug -related uveitis or eye pain or blurred vision that does not respond to topi[INVESTIGATOR_61780] 1 severity within the pre- treatment period or requires 
systemic treatment  
• Any Grade 3  non-skin, drug -related adverse event lasting > 7 days, with the following 
exceptions for drug -related laboratory abnormalities, uveitis, pneumonitis, bronchospasm, 
diarrhea, colitis, neurologic toxicity, hypersensitivity reactions, and infusion reactions:   
− Grade 3 drug- related uveitis, pneumonitis, bronchospasm, diarrhea, colitis, 
neurologic toxicity, hypersensitivity reaction, or infusion reaction of any duration requires discontinuation
  
 
• Grade 3 drug -related laboratory abnormalities do not require treatment discontinuation 
except:   
• Grade 3 drug -related thrombocytopenia > 7 days or associated with bleeding requires 
discontinuation  
• Any drug -related liver function test (LFT) abnormality that meets the following criteria 
require discontinuation:  
o AST o r ALT>8xULN  
o Total bilirubin > [ADDRESS_128152] or ALT > [ADDRESS_128153] and total bilirubin > [ADDRESS_128154]  
 
• Any Grade 4 drug- related adverse event or laboratory abnormality, except for the following 
events, which do not require discontinuation:  
− Grade 4 amylase or lipase abnormalities that are not associated with symptoms or 
clinical manifestations of pancreatitis.  
− Isolated Grade 4 electrolyte imbalances/abnormalities that are not associated with 
clinical sequelae and are corrected with supplementation/appropriate management 
within 72 hours of their onset   
•   Any adverse event, laboratory abnormality, or intercurrent illness which, in the judgment 
of the Investigator, presents a substantial clinical risk to the subject with continued 
nivolumab or ipi[INVESTIGATOR_114567]  4
1 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 41 of 99   (BMS CA209 -444) V.  V6.[ADDRESS_128155] with fever, chills, rigors, headache, rash, pruritis, arthralgias, hypo- or hypertension, bronchospasm, or other symptoms. All Grade 3 or 
4 infusion reactions should be reported within 24 hours as an SAE if criteria are met. Infusion reactions should be graded according to NCI CTCAE (version 4.0) guidelines.  
Treatment recommendations are provided below and may be modified based on local treatment standards and guidelines as appropriate:   
For Grade 1 symptoms: (Mild reaction; Infusion interruption not indicated; intervention not 
indicated) . Remain at bedside and monitor subject until recovery from symptoms. The 
following prophylactic premedications are recommended for future infusions: diphenhydramine 50 mg (or equivalent) and/or paracetamol 325 to 1000 mg (acetaminophen) 
at least 30 minutes before additional nivolumab administrations.  
For Grade 2 symptoms: (Moderate reaction requires therapy or infusion interruption but 
responds promptly  to symptomatic treatment [eg, antihistamines, non- steroidal  anti -
inflammatory drugs, narcotics, corticosteroids, bronchodilators, IV fluids]; prophylactic 
medications indicated for ≤ 24 hours).  Stop the nivolumab and ipi[INVESTIGATOR_114568], begin an IV infusion of normal saline, and treat the 
subject with diphenhydramine 50 mg IV (or equivalent) and/or paracetamol 325 to 1000 mg 
(acetaminophen); remain at bedside and monitor subject until resolution of symptoms.  Corticosteroid or bronchodilator therapy may also be administered as appropriate. If the infusion is interrupted, then restart the infusion at 50% of the original infusion rate when symptoms resolve; if no further complications ensue after 30 minutes, the rate may be increased to 100% of the original infusion rate. Monitor subject closely. If symptoms recur then no further nivolumab or ipi[INVESTIGATOR_114569]. Administer diphenhydramine [ADDRESS_128156] be recorded on the CRF. The following 
prophylactic premedications are recommended for future infusions: diphenhydramine 50 mg (or equivalent) and/or paracetamol 325 to 1000 mg (acetaminophen) should be administered at least 30 minutes before additional nivolumab or ipi[INVESTIGATOR_45782]. If necessary, corticosteroids (recommended dose: up to 25 mg of IV hydrocortisone or equivalent) may be used.  
For Grade 3 or Grade 4 symptoms: (Severe reaction, Grade 3: prolonged [ie, not  rapi[INVESTIGATOR_114570]  4
2 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 42 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in writing by 
[CONTACT_4530].  
 
responsive to symptomatic medication and/or brief interruption of infusion]; recurrence of 
symptoms following initial improvement; hospi[INVESTIGATOR_14138] 
[eg, renal impairment, pulmonary infiltrates]). Grade 4: (life -threatening; pressor or ventilatory 
support indicated). Immediately discontinue infusion of nivolumab or ipi[INVESTIGATOR_125]. Begin an IV 
infusion of normal saline, and treat the subject as follows. Recommend bronchodilators, epi[INVESTIGATOR_238] 0.2 to 1 mg of a 1:1,000 solution for subcutaneous administration or 0.1 to 0.25 mg of a 1:10,000 solution injected slowly for IV administration, and/or diphenhydramine 50 mg IV with methylprednisolone 100 mg IV (or equivalent), as needed. Subject should be 
monitored until the investigator is comfortable that the symptoms will not recur. Nivolumab or 
Ipi[INVESTIGATOR_102341].   
Investigators should follow their institutional guidelines for the treatment of anaphylaxis. 
Remain at bedside and monitor subject until recovery from symptoms. In the case of late-
occurring hypersensitivity symptoms (eg, appearance of a localized or generalized pruritis within 1 week after treatment), symptomatic treatment may be given (eg, oral antihistamine, or corticosteroids).  
 3.5 Treatment Beyond Disease Progression  
Accumulating evidence indicates that a minority of subjects treated with immunotherapy may 
derive clinical benefit despi[INVESTIGATOR_43840].  
Subjects, regardless of study arm, will be permitted to continue treatment beyond initial investigator assessed progression as long as they meet the following criteria:  
• Investigator -assessed clinical benefit  
  and  
• Subject is tolerating study drug.  
 
The assessment of clinical benefit should take into account whether the subject is clinically deteriorating and unlikely to receive further benefit from continued treatment.  
Subjects should discontinue study therapy upon evidence of further progression, defined as an additional 10% or greater increase in tumor burden volume from time of initial progression 
(including all target lesions and new measurable lesions).  
New lesions  are considered measurable at the time of initial progression if the longest 
diameter is at least 10 mm (except for pathological lymph nodes, which must have a short axis 
of at least 15 mm). Any new lesion considered non- measurable at the time of initial 
progression may become measurable and therefore included in the tumor burden 
measurement if the longest diameter increases to at least 10 mm (except for pathological 
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  4
3 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 43 of 99   (BMS CA209 -444) V.  V6.[ADDRESS_128157] 15 mm).  
 3.[ADDRESS_128158]. Any reason for non -compliance should also be documented.  
 3.7 Destruction and Return of Study Drug  
 3.7.1 Destruction of Study Drug  
For this study, study drugs (those supplied by [CONTACT_52240]) such as partially used study drug containers, vials and syringes may be destroyed on site.  
Any unused study drugs can only be destroyed after being inspected and reconciled by [CONTACT_114630], or to meet local regulations (eg, cytotoxics or biologics).  
On-site destruction is allowed provided the following minimal standards are met:  
- On-site disposal practices must not expose humans to risks from the drug.  
- On-site disposal practices and procedures are in agreement
 with applicable laws and 
regulations, including any special requirements for controlled or hazardous 
substances.  
- Written procedures for on- site disposal are available and followed. The procedures 
must be filed with the site’s SOPs and a copy  provided to BMS upon request.  
- Records are maintained that allow for traceability of each container, including the date disposed of, quantity disposed, and identification of the person disposing the containers. The method of disposal, ie, incinerator, licensed sanitary landfill, or 
licensed waste disposal vendor must be documented.  
- Accountability and disposal records are complete, up -to-date, and available for the 
Monitor to review throughout the clinical trial period.  It is the investigator’s 
responsibility to arrange for disposal of all empty containers, provided that procedures 
for proper disposal have been established according to applicable federal, state, local, and institutional guidelines and procedures, and provided that appropriate records of 
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  4
4 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 44 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in writing by 
[CONTACT_4530].  
 
disposal are kept.  
 3.7.2 Return of Study Drug  
Study drug will not be returned to BMS.  Study drug will be destroyed per local institutional 
policy.   
3.8 Immunotherapy Adverse Event Management  
Early recognition and intervention are recommended according to the management 
algorithms; and in addition include ophthalmologic evaluations for any visual symptoms in order to evaluate for nivolumab or ipi[INVESTIGATOR_114571].  
Because of the potential for clinically meaningful nivolumab or ipi[INVESTIGATOR_125]- related AEs 
requiring early recognition and prompt intervention,  management algorithms have been 
developed for suspected pulmonary toxicity, GI toxicity, hepatotoxicity, endocrinopathy, 
skin toxicity, neurological toxicity, and renal toxicity . 
These adverse event management algorithms are included in the
 Appendix Toxic ities . 
 
3.9 Adverse events associated with Stereotactic Body 
Radiation Therapy (SBRT):  
Common side effects (may occur in more than 20 % people receiving treatment; some may be serious):  Fatigue, nausea, vomiting, skin reddening or sensitivity, mild pain, diarrhea, 
decreased appetite, lung scarring, temporary changes in blood work (blood counts or liver enzymes) without symptoms  
 
Occasional side effects (may occur in from 4% - 20% people receiving treatment; some 
may be serious):   Skin thickening or numbness, sores or ulcers near the cancer location, 
cough, shortness of breath, rib pain and/or rib fracture, abdominal pain, fever, irritation of the 
esophagus (swallowing tube); fracture or da mage to the spi[INVESTIGATOR_050].  
 
Rare side effects (may occur in 3 % or fewer of patients receiving treatment; may be 
serious):  Irritation of the lining around the heart or the heart muscle; severe shortness of 
breath;  irritation or damage to spi[INVESTIGATOR_114572]; paralysis; damage to nerves in the chest or abdomen; damage to the esophagus, stomach, or intestines requiring hospi[INVESTIGATOR_64329]; irritation of the large blood vessels around the heart; coughing blood; irritation of the 
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  4
5 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 45 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in writing by 
[CONTACT_4530].  
 
voice box causing hoarseness  or pain; jaundice; abdominal swelling; low blood counts; kidney 
damage; death.  
 
There is also anticipated possible additive toxicities of irradiation during immunotherapy.  Anticipated examples could include increased incidence of pneumonitis in irradiated lung fields and increased incidence of colitis if normal bowel is included in irradiated abdominal fields. 
4 STUDY ASSESSMENTS AND PROCEDURES  
 4.1 Flow Chart/Time and Events Schedule  
 
Procedure  Screening 
Visit  Notes  
Eligibility Assessment  
Informed Consent  X  
Inclusion/Exclusion Criteria  X All inclusion/exclusion criteria should be 
assessed prior to  treatment  
Medical History  X  
Candidate for SBRT as assessed by [CONTACT_114631]  X  
Tumor Tissue  X Patient must have lesion which is not radiated 
and accessible for core biopsies  
Safety Assessment  
Physical Examination  X  
Vital Signs and Oxygen Saturation  X Including BP, HR, & temperature. Obtain at the 
screening visit and within [ADDRESS_128159] 
dose  
Physical Measurements (including 
Performance Status)  X Height and weight and Karnofsky Performance 
Status  
ECG X Within [ADDRESS_128160]  X CBC w/differential, Chemistry panel including: 
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  4
6 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 46 of 99   (BMS CA209 -444) V.  V6.[ADDRESS_128161], ALT, ALP, T.Bili, BUN or serum urea 
level, creatinine, Ca, albumin, Mg, Na, K, Cl, 
glucose, amylase, lipase, TSH, Free T4, Free T3, Hep B/C(HBV sAG, HCV  antibody or HCV RNA), 
within 28  days prior to  treatment. Within 72 
hrs prior to re -dosing  to include CBC w/ 
differential, LFTs, BUN or serum urea level, 
creatinine, Ca, Mg, Na, K, Cl, LDH, Glucose, 
amylase, lipase, TSH (with reflexive Free T4 and Free T3) ,FSH(women under 62)  
Pregnancy Test (WOCBP only)  X With in 28  days prior to treatment . A serum or 
urine pregnancy testing is required within 24 hrs of study treatment then every 4 weeks. 
[more frequently if required by [CONTACT_114632]]. 
After discontinuation from nivolumab these 
should be repeated at approximately 30 days and approximately 70 days [or more frequently 
if required by [CONTACT_114632]].  
Efficacy Assessment  
Screening/Ba seline Tumor Assessments  X CT with contrast of the chest, abdomen, pelvis 
and all known sites of disease (or CT Chest w/o 
contrast and MRI of abdomen with  or without 
contrast if reduced GFR or allergy) . MRI 
(preferred) or CT scan of the Brain if known history of brain involvement. 
Exploratory Biomarker Testing  
Research Biopsy * X Within 28 days prior to  treatment  (optional ) 
and during week 7 on therapy ( optional ) 
Blood Sample  X Within 28 days prior to treatment  and during 
week 7 on therapy  
 
 
*Comment on Biopsies: Participating sites should follow best clinical/institutional practices to 
minimize the harm from tumor biopsies. We recommend  (but not mandate) the peri procedural 
use of tranexamic acid to potentially decrease the risk of bleeding. We recommend tranexamic 
acid [ADDRESS_128162] dose  2 hours prior to biopsy.  
 
 
 
 
 
 
 
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  4
7 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 47 of 99   (BMS CA209 -444) V.  V6.[ADDRESS_128163] be completed and emailed at 
[EMAIL_2255] M—F 8am to 5pm CST.  
• Signed/dated patient consent form  
• Eligibility checklist  
• Copi[INVESTIGATOR_114573]/chemotherapy  or radiation therapy  
• Screening labs(including pregnancy test)/vital signs and EKG  
• CT  reports  
• Other materials may also be sent if considered pertinent for confirming patient 
eligibility, e.g. CT/MRI of C/A/P  
 
The Lead Center will review the documents to confirm eligibility.  To complete the registration process the Lead Center will:  
• Assign a patient study number  
• Patients found to be ineligible for participation after being consented will be 
considered screen failures, and documented as such in the Screening and 
Enrollment Log 
• New subjects will receive a number beginning with [ADDRESS_128164] consented receives the number 002, etc.  
• Upon confirmation of eligibility and enrollment as per the afore -mentioned 
instructions, the subject will be assigned a secondary number in the order of enrollment. For example, subject [ADDRESS_128165] 003 
will become 003- 02 and so- on.  
 
• For UTSW, each newly consented subject should be numbered using the schema provided above. Upon registration, the registrar will assign the additional registration/randomization code according to the numbering schema outlined above, which should then be entered as the patient study id in Velos upon updating the status to enrolled.  
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  4
8 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 48 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in writing by 
[CONTACT_4530].  
 
 
• The numbering schema should clearly identify the site number; the sequential 
number of the subject enrolled as well as the status of the subjects enrolled so 
that the number of subjects consented versus the number of subjects actually enrolled may be easily identified.   
 
  
 
   
 
  
 
  
 
  
 
  
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  4
9 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 49 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in writing by [CONTACT_4530].  
 
4.3 Study Calendar  
The Investigator may perform more frequent examinations than shown in Table below if clinically indicated. Data from such additional examinations 
are also to be reported in the eCRF.  
 
* baseline visit and W1D1 can be 
combined  Screening  Baseline 
Visit * 
 Induction Phase  
Cycle a 1 and 2  Maintenance Phase  
Cycle  a 3 and every 
subsequent cycle (8 
weeks)  
(up to 2 years)  30 day  
Follow -
upr 
(X1) Follow -up 
Visits s 
(X2 and X3)  Survival 
Follow -
Upt 
 D -28 to 0  D-3 to D 
1 W1D1* 
(C1W1)  W4D1  
(C1W4)  W7D1 
(C2W1)  W10D1  
(C2W4)  W1D1  
 W5D1 
     
Informed consent X            
Inclusion/Exclusion Criteria  X p            
Archival Tumor Tissueb X            
Nivolumab c   X X X X X X     
Ipi[INVESTIGATOR_125] d   X X X X       
SBRT e   X e         
Medical history X X           
Physical assessment  X X X X X X X X  X X  
Vital signs f X X X X X X X X  X X  
Height  X            
Performance status g X X X X X X X X  X X  
Pulse Oximetry h   X X X X X X     
EKG X            
Adverse Events Assessment    X X X X X X  X X  
Concomitant Medications  X X X X X X X X  X X  
Disease Assessment i X every 6 weeks (± 1 wk)  for the first 13 months from treatment and every 12 weeks (± 1 wk) thereafter, until 
disease progression is documented or treatment is discontinued (whichever occurs later)   
CBC with diff J X X q X X X X X X  X X  
Comp Panel K X X q X X X X X X  X X  
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  5
0 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 50 of 99   (BMS CA209 -444) V.  V6.[ADDRESS_128166] l X X X X X X X X  X X  
 Screening  Baseline 
Visit  
 Induction Phase  
Cycle a 1 and 2  Maintenance Phase  
Cyclea 3 and every 
subsequent cycle (8 
weeks)  
(up to 2 years)  30 day  
Follow -up 
r 
(X1) Follow -up 
Visits s 
(X2 and X3)  Survival 
Follow -
Up t 
 D-28 to 0  D-3 to D1  W1D1 
(C1W1)  W4D1  
(C1W4)  W7D1  
(C2W1)  W10D1  
(C2W4)  W1D1  
 W5D1 
     
Hep B or Hep C m X            
Research biopsy n X    X     X   
Blood sample o X    X     X   
Survival Follow -Up t            X 
a. 1 cycle = 6 weeks  
b. Archival Formalin -fixed paraffin -embedded (FFPE) tumor tissue must be available for correlative studies (Note: Fine Needle Aspi[INVESTIGATOR_1516] [FNA] and bone metastases samples are not acceptable for subm ission)  
c. Nivolumab is to be administered as an approximately [ADDRESS_128167].  
e. SBRT (5 fractions of 10 Gy) is to be delivered anytime between Day 1 of Week 1 (Cycle 1) and Day 1 of Week 4 (Cycle 1) of the nivolumab and ipi[INVESTIGATOR_114574]  (within the first 3 weeks after the 
initiation of nivolumab and ipi[INVESTIGATOR_125]) . SBRT is preferred to be delivered in the  first 2 weeks.  
f. Temp, Pulse, B.P., Weight  
g. Karnofsky Performance Status  
h. Oxygen saturation by [CONTACT_114633] (at rest and with exertion) Also perform if any new or worsening pulmonary symptoms present  
i. CT with contrast of  the chest, abdomen, pelvis and all known sites of disease (or CT Chest w/o contrast and MRI of abdomen with or without contra st if reduced GFR or allergy). MRI (preferred) or CT scan of 
the Brain if kno wn history of brain involvement (all known sites of d isease should be assessed at baseline)  
j. CBC w/differential and platelets  
k.  Full Chemistry Panel including: LDH, AST, ALT, ALP, T.Bili, BUN, creatinine, Ca+, Mg+, Na -, K+, HCO3 -, Cl-, glucose, albumin, T.Protein, amylase, lipase  
l. WOCBP only (serum or urine)  a t screening and within 24 hours of dosing  
m. HepB sAg & HCV Ab or HCV RNA  
n.  Multiple tumor biopsies – pre-treatment  (optional ), at week 7 of treatment (optional) and at the time of progression (optional)  
o. Blood samples will be collected for research at pre -treatment, at week [ADDRESS_128168]. Danny Song (JHU), [CONTACT_114661] (UTSW) or co- investigator Radiation Oncologist from the Radiation Therapy Departme nt to 
determine eligibility/feasibility for SBRT. The cancer lesion(s) to be radiated should be determined by [CONTACT_114634]/Medical Oncologist  
q. Cycle 1 Day 1 labs do not need to be performed if don e ≤ 72 hours of dosing as part of the Day - 3 to +1 labs  
r. Perform 30 days ± 1week from last dose of study drug  
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  5
1 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 51 of 99   (BMS CA209 -444) V.  V6.[ADDRESS_128169] 8 weeks (+/ - 1 week) after last dose of nivolumab was administered and visit X3 will take place 15 weeks (+/ - 1 week) after last  dose of nivolumab was administered.  If additional X follow -up 
visits are required due to ongoing study drug - related toxicity, they should take place every 8 weeks (+/ - 1 week) until study drug -related toxicity has resolved, stabilized or been deemed irreversible.  
t. Study subjects will be contact[CONTACT_457] 3 months for survival data. Other potential data such as the subjects’ follow -up treatment or care may be requested during these contacts.  The contacts can be via 
telephone or correspond with disease assessment visits  or other scheduled visits  
u. Free T3 & Free T4 if TSH not within normal limits  
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  5
2 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 52 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in 
writing by [CONTACT_4530].  
 
 4.4 Safety Assessments / Considerations   
At baseline, a medical history will be obtained to capture relevant underlying 
conditions. The baseline examinations should include weight, height, Karnofsky Performance Status, BP, HR, and temperature. Baseline signs and symptoms are those that are assessed within 28 days prior to treatment . Concomitant medications 
will be collecte d from within 28 days prior to treatment .   
Baseline local laboratory assessments should be done within 28 days prior to 
treatment to include: CBC w/differential, LFTs (ALT, AST, total bilirubin, alkaline 
phosphatase), BUN or serum urea level, creatinine, Ca, albumin, Mg, Na, K, Cl, LDH, 
glucose, amylase, lipase, TSH, Free T4, Free T3, and Hep B and C testing (HBV sAg, 
HCV Ab or HCV RNA).  
Pregnancy testing for WOCBP must be performed within 24 hours prior to the initial 
administration of study drug at baseline and then every 4 week s during the treatment 
period and at the safety follow -up visits. After discontinuation from nivolumab these 
should be repeated at approximately 30 days and approximately 70 days [or more frequently if required by [CONTACT_114632]].  If, following in itiation of the investigational 
product, it is subsequently discovered that a study subject is pregnant  or may have 
been pregnant at the time of investigational product exposure, including during at 
least [ADDRESS_128170] will be permanently discontinued in an appropriate manner (eg, dose tapering if necessary for 
subject safety). The investigator must immediately notify Worldwide Safety @BMS of this event via the Pregnancy Surveillance Form in accordance with SAE reporting procedures. Follow -up information regarding the course of the pregnancy, including 
perinatal and neonatal outcome and, where applicable, offspring information must be reported on the Pregnancy Surveillance Form [provided upon request f rom BMS].Any 
pregnancy that occurs in a female partner of a male study participant should be reported to BMS. Information on this pregnancy will be collected on the Pregnancy Surveillance Form.  
Subjects will be evaluated for safety if they have received any study drug. Toxicity assessments will be continuous during the treatment phase. During the safety follow -
up phase (6 weeks), toxicity assessments should be done . Once subjects reach the 
survival follow -up phase either in person or documented telephone calls to assess the 
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  5
3 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 53 of 99   (BMS CA209 -444) V.  V6.[ADDRESS_128171]’s status are acceptable. Adverse events and laboratory values will be graded 
according to the NCI -CTCAE version 4.0.  
On-study weight and  Karnofsky Performance status and vital  signs should be 
assessed at each on- study visit. Vital signs should also be taken as per institutional 
standard of care prior to, during and after dosing. Oxygen saturation by [CONTACT_114635]- study visit prior to dosing . 
The start and stop times of nivolumab and ipi[INVESTIGATOR_114575]. Physical examinations are to be performed as clinically indicated. If there are any new or worsening clinically significant changes since the last exam, report changes on the 
appropriate non- serious or serious adverse event page.  
On study local laboratory assessments should be done within 72 hours of dosing to 
include; CBC w/differential, LFTs (ALT, AST, total bilirubin, alkaline phosphatase), BUN or serum urea level, creatinine, Ca, Mg, Na, K, Cl, LDH, glucose, amylase, lipase, TSH with reflexive Free T4, Free T3 on Day 1 of Weeks 1 and 4 for Cycles 1 and 2 and on Day 1 of Weeks 1 and 5 starting from Cycle 3. Additional measures including non-study required laboratory tests should be performed as clinically indicated or to 
comply with local regulations. Laboratory toxicities (eg, suspected drug inducted liver enzyme elevations) will be monitored during the follow -up phase via on site/local labs 
until all study drug related toxicities resolve, return to baseline or are deemed irreversible. In addition, LFTs should also be assessed prior to the second dose of each cycle. The results of these labs should be reviewed prior to dosing. Amylase, 
Lipase and thyroid tests must be drawn, but do not need to be resulted prior to infusion unless patient is symptomatic.  The following laboratory abnormalities should be documented and reported appropriately:  
• any laboratory test result that is clinically significant or meets the definition of 
an SAE 
• any laboratory abnormality that required the subject to have study drug 
discontinued or interrupted 
• any laboratory abnormality that required the subject to receive specific 
corrective therapy.  
Oxygen saturation by [CONTACT_114636] a subject has any new or worsening respi[INVESTIGATOR_1856]. A reading at rest 
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  5
4 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 54 of 99   (BMS CA209 -444) V.  V6.[ADDRESS_128172] throughout the study. If the patient’s status changes, the investigator can alter the extent of exertion based on their medical judgm ent. If a 
subject shows changes on pulse oximetry or other pulmonary related signs (hypoxia, fever) or symptoms (eg, dyspnea, cough, fever) consistent with possible pulmonary adverse events, the patient subject should be immediately evaluated to rule out 
pulmonary toxicity.  An algorithm for the management of suspected pulmonary 
toxicit y can be found in the appendix of the nivolumab Investigator’s Brochure.  
Some of the previously referred to assessments may not be captured as data in the 
CRF. They are intended to be used as safety monitoring by [CONTACT_1963]. Additional testing or assessments may be performed as clinically necessary or where required by [CONTACT_53933].  
Overdose:  An overdose is defined as the accidental or intentional administration of 
any dose of a product that is considered both excessive and medically important. All occurrences of overdose must be reported as an SAE.  
Other Safety Considerations:  Any significant worsening noted during interim or final 
physical examinations, electrocardiograms, x rays, and any other potential safety 
assessments, whether or not these procedures are required by [CONTACT_760], should 
also be recorded as a nonserious or serious AE, as appropriate, and reported accordingly.  
4.[ADDRESS_128173] medical/clinical judgment.  
 4.5.1 CT/MRI 
Both, contrast -enhanced Computed Tomography (CT) and Magnetic Resonance 
Imaging (MRI) scans acquired on dedicated CT/MRI equipment are adequate imaging modalities for this study.  
CT scans should be acquired with 5 mm slices with no intervening gap (contiguous). Subjects who cannot receive IV contrast at the start of study should be imaged by [CONTACT_114637][INVESTIGATOR_125]  5
5 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 55 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in 
writing by [CONTACT_4530].  
 
of abdomen/pelvis with IV contrast and CT of chest without contrast. MRIs should be 
acquired with 5 mm slices with no intervening gap (contiguous).  Subsequent 
assessments should include chest, abdomen, and pelvis, and all known sites of disease and should use the same imaging method as was used at baseline. Patients initially imaged with CT of chest, abdomen, and pelvis with IV contrast who can no longer receive contrast can be monitored by [CONTACT_114638], abdomen, and pelvis without IV contrast. Every attempt should be made to image each subject using an identical acquisition protocol on the same scanner for all imaging time.  
 4.5.2 MRI/ CT Brain  
MRI (preferred) or CT of brain  (with contrast)  is required at screening only when  
metastatic disease  to the brain is suspected or known. MRI or CT brain scans during 
on-study treatment and follow up periods are required only if clinically indicated for new 
signs and symptoms that suggest CNS involvement or progression.  
4.[ADDRESS_128174], abdomen, pelvis, and brain, all known 
sites of disease should be assessed at baseline.  
 4.6.2 Response Criteria  
Subjects will be evaluated for tumor response beginning 6 weeks  weeks (± 1 wk) from 
treatment and continuing every 6 weeks (± 1 wk) for the first 13 months from treatment 
and every 12 weeks (± 1 wk) thereafter,  until disease progression is documented or 
treatment is discontinued (whichever occurs later).  
4.6.[ADDRESS_128175] (Response Evaluation Criteria in Solid Tumors) 1.[ADDRESS_128176] when a treatment is working and measures 
of progression indicate when a drug should be stopped.  
 
Measurable disease  
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  5
6 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 56 of 99   (BMS CA209 -444) V.  V6.[ADDRESS_128177] one 
dimension (longest diameter in the plane of measurement is to be recorded) with a 
minimum size of:  
- [ADDRESS_128178] scan (CT scan slice thickness no greater than 5 mm)    
- 10 mm caliper measurement by [CONTACT_461] (lesions which cannot be 
accurately measured with calipers should be recorded as non- measurable)  
- [ADDRESS_128179] x -ray   
Malignant lymph nodes: To be considered pathologically enlarged and measurable, a 
lymph node must be ≥ [ADDRESS_128180] scan (CT scan 
slice thickness recommended to be no greater than 5 mm).  
 
Nonmeasurable disease  
Following RECIST  1.1, all other lesions (or sites of disease) will be considered 
nonmeasurable disease. This includes small lesions (longest diameter < 20 mm with 
conventional techniques or < [ADDRESS_128181] scan) and any of the following:  
• bone lesions  
• ascites  
• pleural or pericardial effusion  
• lymphangitis cutis or pulmonis  • abdominal masses that are not confirmed and followed by [CONTACT_15218]  
• cystic lesions  
• lesions occurring within a previously irradiated area unless they are documented as new lesions since the completion of radiation therapy   
4.6.[ADDRESS_128182]  1.1, progression in a nodal or visceral site (ie, liver and lung) is 
sufficient to document disease progression. The presence or absence of nodal and 
visceral disease before and after treatment should be recorded separately.  
All measurable lesions (up to a maximum of 5 lesions per organ and 10 lesions in total) will be identified as target lesions to be measured and recorded at baseline. The target 
lesions should be representative of all involved organs. Target lesions will be selected 
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  5
7 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 57 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in 
writing by [CONTACT_4530].  
 
on the basis of size (ie, the largest area) and suitability for accurate, repeated 
measurements (either by [CONTACT_14217]). The sum of the longest diameter (LD) of all target lesions will be calculated and reported as the baseline sum LD. The baseline sum LD will be used as a reference by [CONTACT_14218].  
Because small lymph nodes are difficult to measure accurately and may not be malignant, the greatest diameter of a ly mph node must measure at least 1.[ADDRESS_128183] response criteria for target lesions  
 
Response  Evaluation of Soft -Tissue Lesions  
Complete response (CR)  The disappearance of clinical and radiological evidence of all target lesions 
and normalization of tumor marker levels  
Partial response (PR)  A decrease from baseline ≥ 30% in the sum of the LD of all target lesions  
Progressive disease (PD)  An increase  ≥ 20% in the sum of the LD of all target lesions based on the 
smallest sum LD since treatment started or the appearance of one or more 
new lesions or the appearance of new lesions  
Stable disease (SD)  Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify 
for PD based on the smallest sum LD recorded since treatment started  
4.6.[ADDRESS_128184] the actual short axis measurement recorded (measured in the same anatomical plane as the baseline examination), even if the nodes regress to below 10 mm on study. This means that 
when lymph nodes are included as target lesions, the ‘sum’ of lesions may not be zero 
even if complete response criteria are met, since a normal lymph node is defined as having a short axis of < [ADDRESS_128185] achieve a short axis < 10 mm. For PR, SD and PD, the actual short axis measurement of the nodes is to be included in the sum of target lesions.  
 
Target lesions that become ‘too small to measure’  
While on study, all lesions (nodal and non- nodal) recorded at baseline should have 
their actual measurements recorded at each subsequent evaluation, even when very 
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  5
8 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 58 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in 
writing by [CONTACT_4530].  
 
small (eg, 2 mm). However, sometimes lesions or lymph nodes which are recorded as 
target lesions at baseline become so faint on CT scan that the radiologist may not feel comfortable assigning an exact measure and may report them as being ‘too small to measure’. When this occurs it is important that a value be recorded on the case report form. If it is the opi[INVESTIGATOR_26191], the measurement should be recorded as 0 mm. If the lesion is believed to be present and is faintly seen but too small to measure, a default value of 5 mm should be assigned (Note: It is less likely that this rule will be used for lymph nodes since they usually have a definable size when normal and are frequently surrounded by [CONTACT_104178]; however, if a lymph node is believed to be present and is faintly seen 
but too small to measure, a default value of 5 mm should be assigned in this circumstance as well). This default value is derived from the [ADDRESS_128186] slice thickness (but should not be changed with vary ing CT slice thickness). The measurement of 
these lesions is potentially non- reproducible, therefore providing this default value will 
prevent false responses or progressions based upon measurement error. To reiterate, however, if the radiologist is able to provide an actual measure, that should be recorded, even if it is below 5 mm.  
 
Lesions that split or coalesce on treatment  
When non -nodal lesions ‘fragment’, the longest diameters of the fragmented portions 
should be added together to calculate the target lesion sum. Similarly, as lesions coalesce, a plane between them may be maintained that would aid in obtaining maximal diameter measurements of each individual lesion. If the lesions have truly coalesced such that they are no longer separable, the vector of the longest diameter in this instance should be the maximal longest diameter for the ‘coalesced lesion’.  
4.6.[ADDRESS_128187] response criteria for non -target lesions  
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  5
9 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 59 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in 
writing by [CONTACT_4530].  
 
 
Response  Evaluation of Soft -Tissue Lesions  
Complete response (CR)  Disappearance of all non -target lesions and normalization of tumor marker 
level. All lymph nodes must be non -pathological in size (< 10mm short axis)  
Non -CR/Non -PD Persistence of one or more non -target lesion(s) and/or maintenance of 
tumor marker level above the normal limits  
Progressive disease (PD)  Unequivocal progression (see comments below) of existing non - target 
lesions. (Note: the appearance of one or more new lesions is also considered 
progression)  
 
4.6.7.  Special Notes on Assessment of Progression of Non- Target Disease  
The concept of progression of non- target disease requires additional explanation as 
follows:  
When the patient also has measurable disease  
In this setting, to achieve ‘unequivocal progression’ on the basis of the non- target 
disease, there must be an overall level of substantial worsening in non -target disease 
such that, even in presence of SD or PR in target disease, the overall tumor burden 
has increased sufficiently to merit discontinuation of therapy. A modest ‘increase’ in the size of one or more non- target lesions is usually not sufficient to qualify for 
unequivocal progression status. The designation of overall progression solely on the basis of change in non- target disease in the face of SD or PR of target disease will 
therefore be extremely rare.  
When the patient has only non -measurable disease  
This circumstance arises in some trials when it is not a criterion of study entry to have 
measurable disease. The same general concepts apply here as noted above, however, 
in this instance there is no measurable disease assessment to factor into the 
interpretation of an increase in non- measurable disease burden. Because worsening 
in non- target d isease cannot be easily quantified (by [CONTACT_108]: if all lesions are truly 
non-measurable) a useful test that can be applied when assessing patients for 
unequivocal progression is to consider if the increase in overall disease burden based on the change in non- measurable disease is comparable in magnitude to the increase 
that would be required to declare PD for measurable disease: ie, an increase in tumor burden representing an additional 73% increase in ‘volume’ (which is equivalent to a 
20% increase diameter in a measurable lesion). Examples include an increase in a 
pleural effusion from ‘trace’ to ‘large’, an increase in lymphangitic disease from localized to widespread, or may be described in protocols as ‘sufficient to require a 
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  6
0 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 60 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in 
writing by [CONTACT_4530].  
 
change in therapy’. If ‘unequivocal progression’ is seen, the patient should be 
considered to have had overall PD at that point. While it would be ideal to have 
objective criteria to apply to non -measurable disease, the very nature of that disease 
makes it impossible to do so; therefore the increase must be substantial.  
 4.6.8 New Lesions  
The appearance of new malignant lesions denotes disease progression; therefore, some comments on detection of new lesions are important. There are no specific criteria for the identification o f new radiographic lesions; however, the finding of a new 
lesion should be unequivocal: ie, not attributable to differences in scanning technique, change in imaging modality or findings thought to represent something other than tumor (for example, some ‘new’ bone lesions may be simply healing or flare of pre-existing lesions). This is particularly important when the patient’s baseline lesions show partial or complete response. For example, necrosis of a liver lesion may be reported on a CT scan report as a ‘new’ cystic lesion, which it is not.  
A lesion identified on a follow -up study in an anatomical location that was not scanned 
at baseline is considered a new lesion and will  indicate disease progression.  
 4.6.[ADDRESS_128188] response recorded from the start of treatment until either disease progression or recurrence. The investigator’s determination of best overall response will be based both on response criteria and on confirmation criteria. To be assigned a status of partial response or complete response, changes in tumor 
measurements must be confirmed by [CONTACT_114639] [ADDRESS_128189] documented. Table 9 can be used as an assessment tool.  
Table 9. Assessing Overall Response  
Target Lesions  Non -target Lesions  New Lesions  Overall Response  
CR  CR  No  CR  
CR  Incomplete 
response/SD  No  PR  
PR  Non -PD  No  PR  
SD  Non -PD  No  SD  
PD  Any  Yes or No  PD  
Any  PD  Yes or No  PD  
Any  Any  Yes  PD  
Abbreviations: CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.  
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  6
1 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 61 of 99   (BMS CA209 -444) V.  V6.[ADDRESS_128190] tumor response assessment due to rapid progression or toxicity will be considered non- responders, will be included in the denominator for the 
response rate, and will be classified into one of the categories listed below:  
• death attributed to disease progression  
• early discontinuation attributed to disease progression  
• death attributed to drug toxicity  • early discontinuation attributed to drug toxicity  
Note : If a patient receives subsequent therapy before tumor progression is 
documented, the reason for changing therapy must be reported. Reasons include clinical progression, drug toxicity, or secondary therapy for maintaining tumor response.  
 4.6.10 Confirmation Scans 
Verification of Response:  To be assigned a status of CR or PR, changes in tumor 
measurements must be confirmed by [CONTACT_114640] [ADDRESS_128191] met. For this 
study, th e next scheduled tumor assessment can meet this requirement.  
Verification of Progression: Progression of disease should be verified in cases 
where progression is equivocal. If repeat scans confirm PD, then progression should be declared using the date of the initial scan. If repeat scans do not confirm PD, then the subject is considered to not have progressive disease.  
4.[ADDRESS_128192] the immunomodulatory properties and eff icacy of 
nivolumab plus ipi[INVESTIGATOR_114576]/ or during 
treatment  and/or progression as outlined in Table 10.  
Table 10. Correlative studies 
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  6
2 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 62 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in 
writing by [CONTACT_4530].  
 
Analysis  Sample  Assay Time Points  
Tissue staining 
(PDL1, CD8 etc)  Archival and FFPE biopsy tissue  IHC/IF  Archiva l tissue, 
Baseline Biopsy, 
Week 7 Biopsy , 
Biopsy at time of 
progression  
Soluble Factors/ Cytokines  Serum  Luminex xMAP, Immunology Core  Baseline Blood 
sample, Week 7 Blood 
sample, Blood sample 
at time of progression  
Immune Gene Expression  
Mutational Analysis  FFPE biopsy tissue  
RNA Later  Nanostring nCounter, RNAseq  
Whole Exome seq  Baseline Biopsy, 
Week 7 Biopsy, Biopsy at time of 
progression  
T-Cell receptor 
sequencing  Frozen tumor biopsy, PBMC  Adaptive Bio, Immunoseq  Baseline 
Biopsy/Blood, Week 7 Biopsy/Blood, Biopsy/Blood at time 
of progression  
ELISPOT Assay  Frozen PBMC  Immunology Core  Baseline Biopsy, 
Week 7 Biopsy, Biopsy at time of 
progression  
Humoral Immune Response Plasma  Protoarray (Life Tech), Microarray Core  
UTSW Immunology Core  Baseline Blood 
sample, Blood sample at Week 7 Biopsy, Blood sample at time 
of progression  
Cell Culture  Biopsy material  Hammers Lab  Baseline Biopsy   
 
Optional research biopsy at week 7 Optional Tumor Biopsy:  
A week [ADDRESS_128193] scan may be done to determine where the biopsy will be done (CT -guided biopsy) or the biopsy may be done via Ultra sound guidance.  
 
 
  
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  6
3 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 63 of 99   (BMS CA209 -444) V.  V6.[ADDRESS_128194]  safety and care.  
 
All subjects experiencing an adverse event, regardless of its relationship to study drug, will be monitored until:  
 the adverse event resolves or the symptoms or signs that constitute the adverse event return to baseline;  
 any abnormal laboratory values have returned to baseline;  
 there is a satisfactory exp lanation other than the study drug for the 
Cycle [ADDRESS_128195] --study 
Follo w--up  
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  6
4 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 64 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in 
writing by [CONTACT_4530].  
 
changes observed; or  
 death.  
 
5.1 Definition and Grade   
Adverse Events will be reported as indicated by [CONTACT_114641] 
(see below).   An adverse event  is defined as any untoward or unfavorable medical 
occurrence in a human research study participant, including any abnormal sign (for example, abnormal physical exam , imaging finding or clinically significant  
laboratory finding), symptom, clinical event, or disease, temporarily associated with the subject’s participation in the research, whether or not it is considered related to the subject’s participation in the research.  
Adverse events encompass clinical, physical and psychological harms. Adverse events  occur most commonly in the context of biomedical research, although on 
occasion, they can occur in the context of social and behavioral research. Adverse events may be expected or unexpected. 
Acute Adverse Events  
Adverse events occurring in the time period from the signing of the informed 
consent through [ADDRESS_128196] treatment will be considered acute adverse events.  
Severity  
Adverse events will be graded by a numerical score according to the defined NCI Common Terminology Criteria for Adverse Events (NCI CTCAE  version 4) and 
version number specified in the protocol. Adverse events not specifically defined 
in the NCI CTCAE will be scored on the Adverse Event log according to the general guidelines provided by [CONTACT_114642].   
•  Grade 1: Mild  
•  Grade 2: Moderate  
•   Grade 3: Severe or medically significant but not immediately life threatening 
•   Grade 4: Life threatening consequences  
•   Grade 5: Death related to the adverse event  
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  6
5 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 65 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in 
writing by [CONTACT_4530].  
 
Serious Adverse Events  
ICH Guideline E2A and the UTSW IRB define serious adverse events as those 
events, occurring at any dose, which meets any of the following criteria:  
• Results in death   
• Immediately life -threatening  
• Results in inpatient hospi[INVESTIGATOR_059] 1,2 or prolongation of existing hospi[INVESTIGATOR_059]  
• Results in persistent or significant disability/incapacity  
• Results in a congenital anomaly/birth defect  
• Based upon appropriate medical judgment, may jeopardize the subject’s health 
and may require medical or surgical intervention to prevent one of the other outcomes listed in this definition.  
Note: A “Serious adverse event” is by [CONTACT_114643]. Serious adverse events may or may not be related to the research project. A serious  adverse event determination does not require the event to be 
related to the research. That is, both events completely unrelated to the condition under study and events that are expected in the context of the condition under study may be serious adverse events, independent of relatedness to the study itself. As examples, a car accident requiring >24 hour inpatient admission to the 
hospi[INVESTIGATOR_114577] a serious adverse event for any research participant; likewise, 
in a study investigating end- stage cancer car e, any hospi[INVESTIGATOR_114578] -specified period of monitoring for adverse and serious 
adverse events would be a serious adverse event, even if the event observed is 
a primary clinical endpoint of the study.  
1Pre-planned hospi[INVESTIGATOR_114579]. Note: If events 
occur during a pre- planned hospi[INVESTIGATOR_64329], that prolong the existing hospi[INVESTIGATOR_059], 
those events should be evaluated and/or reported as SAEs.   
2 NCI defines hospi[INVESTIGATOR_114580] 24 hours. Hospi[INVESTIGATOR_114581]. For example: a hospi[INVESTIGATOR_114582] a patient is admitted for observation or minor treatment (e.g. hydration) and released in less than 24 hours. Furthermore, hospi[INVESTIGATOR_114583] a routine AE or in an expedited report.  
 
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  6
6 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 66 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in 
writing by [CONTACT_4530].  
 
 5.2 Unanticipated Problems:  
The phase  “unanticipated problems involving risks to subjects or others ” is fou nd, 
but not defined in the HHS regulations at 45 CFR 46, and the FDA regulations at 
21 CFR 56.   108(b)(1) and [ADDRESS_128197], which is defined in 21 CFR 812.3(s). Guidance from 
the regulatory agencies considers unanticipated problems to include any incident, 
experience, or outcome that meets ALL three (3) of the following criteria:  
• Unexpected (in terms of nature, severity or frequency)   given (a) the research 
procedures that are described in the protocol -related documents, such as the 
IRB-approved research protocol and informed consent document; and (b) the 
characteristics of the subject population being studied;  
•                                                            AND 
• Related or possibly related to participation in the research(possibly related 
means there is a reasonable possibility that the incident, experience, or 
outcome may have been caused by [CONTACT_3459]);  
•                                                               AND  
• Suggests that  the research places subjects or others at greater risk of harm 
(including  physical, psychological, economic, or social harm) than was 
previously known or recognized. Note: According to OHRP, if the adverse event 
is serious, it would always suggest a  greater risk of harm.  
Follow -up  
All adverse events will be followed up according to good medical practices.  
  
5.3 Reporting  SAEs and UPI[INVESTIGATOR_114584](SCCC) Data Safety 
Monitoring Committee (DSMC)  
All SAE/UPI[INVESTIGATOR_114585], which occur in research subjects on protocols for which the 
SCCC is the DSMC of record require reporting to the DSMC regardless of whether IRB reporting is required. All SAEs/UPI[INVESTIGATOR_114586]- specified 
monitoring period should be submitted to the SCCC DSMC within 5 business days of the PI [INVESTIGATOR_114587](s). In addition, for 
 
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  6
7 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 67 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in 
writing by [CONTACT_4530].  
 
participating centers other than UTSW, local IRB guidance should be followed for 
local reporting of serious adverse events. .  
The UTSW study team is responsible for submitting SAEs/UPI[INVESTIGATOR_114588].  Hardcopi[INVESTIGATOR_114589]; FDA 
Form #3500A forms, or other sponsor forms, if applicable; and/or any other supporting 
documentation available should be submitted to the DSMC Coordinator.  The DSMC Coordinator forwards the information onto the DSMC Chairman who determines if 
immediate action is required.  Follow -up eIRB reports, and all subsequent SAE/UPI[INVESTIGATOR_114590]
 
5.3.1 Reporting Unanticipated problems Involving Risks to Subjects or  
Others(UPI[INVESTIGATOR_20865])  
           UT Southwestern reportable event guidance applies to all research conducted 
by [CONTACT_114644], its affiliates, and investigators, sites, or institutions 
relying on the UT Southwes tern IRB.  Additional reporting requirements apply for research 
relying on non -UT Southwestern IRB.  
According to UTSW HRPP/IRB policy, UPI[INVESTIGATOR_114591], experiences,         
outcomes, etc. that meet ALL three (3) of the following criteria:  
1. Unexpected in nature, frequency, or severity (i.e., generally not expected 
in a subject’s underlying condition or not expected as a risk of the study; therefore, not included in the investigator’s brochure, protocol, or informed consent document),AND  
2. Probably or definitely related to participation in the research, AND  
3. Suggests that the research places subjects or others at a greater risk of 
harm (including physical, psychological, economic, or social harm) than 
was previously known or recognized.  Note: According to OHRP, if the 
adverse event is serious, it would always suggest a greater risk of harm.  
 
For purposes of this policy, UPI[INVESTIGATOR_114592] (     
UADEs) and death or serious injury related to a humanitarian use device (HUD).  
 
UPI[INVESTIGATOR_114593] 5 working days of  PI 
[INVESTIGATOR_38417].  
 
For research relying on a non- UT Southwestern IRB (external, central, or single IRB) :  
Investigators relying on an external IRB who are conducting research on behalf of UT 
Southwestern or its affiliates are responsible for submitting LOCAL UPI[INVESTIGATOR_114594] 5 working days of PI [INVESTIGATOR_38417].  Investigators much report to their relying IRB according to the relying IRBs policy.  In addition, the external IRB’s responses or 
determinations are these local events must be submitted to the UT Southwestern IRB within 
10 working days of receipt.   
 
Events not meeting UPI[INVESTIGATOR_114595]:  
Events that do NOT meet UPI[INVESTIGATOR_114596], evaluated, summarized and 
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  6
8 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 68 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in 
writing by [CONTACT_4530].  
 
submitted to the UTSW HRPP/IRB at continuing review.  
For more information on UTSW HRPP/IRB reportable event policy, see  
https://www.utsouthwestern.edu/research/research -administration/irb/assets/policies -
combines.pdf.  
4.  
 
  
5.3.2  SAE   
  
 
If the event occurs on a multi -institutional clinical trial coordinated by [CONTACT_114645], the DOT Manager or lead coordinator 
ensures that all participating sites are notified of the event and resulting  action, 
according to FDA guidance for expedited reporting. DSMC Chairperson reviews 
all SAEs/UPI[INVESTIGATOR_114597].  The DSMC 
Chairperson determines whether action is required and either takes action immediately, convenes a special DSMC session (physical or electronic), or defers the action until a regularly scheduled DSMC meeting.  
  
 
 
Telephone reports to: 
PI:  [INVESTIGATOR_114598], MD  
Email:  [EMAIL_2256]  
Lead Site Protocol Coordinator:  Allison Beaver, RN  
Email:  [EMAIL_2257]  
Phone:  214 -645-8787  
Written reports to:  
PI:  [INVESTIGATOR_114598], MD  
Email:  [EMAIL_2256]  
Lead Site Protocol Coordinator:  Allison Beaver, RN  
Email:  [EMAIL_2257]  
Fax:  214- 645-8767  
 
UTSW SCC Data Safety Monitoring Committee Coordinator  
Email: [EMAIL_2258]  
Fax: 214- 648-[ADDRESS_128198] (IRB)  
Submit via eIRB with a copy of the final sponsor report as attached supporting 
documentation  
  
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  6
9 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 69 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in 
writing by [CONTACT_4530].  
 
 
5.4  Steps to Determine If an Adverse Event Requires 
Expedited Reporting to the SCC DSM C and/or HRPP 
Step 1 :  Identify the type of adverse event using the NCI Common Terminology Criteria 
for Adverse Events (CTCAE v4).        
 Step 2 : Grade the adverse event using the NCI CTCAE v4.  
 
Step 3: Determine whether the adverse event is related to the protocol therapy  
Attribution categories are as follows:  
- Definite – The AE is clearly related  to the study treatment.  
- Probable – The AE is likely related to the study treatment.  
- Possible – The AE may be related  to the study treatment.  
- Unlikely -The AE may NOT be related to the study treatment.  
- Unrelated – The AE is clearly NOT related  to the study treatment.  
Note : This includes all events that occur within 100days of the last dose of protocol 
treatment.  Any event that occurs more than100 days after the last dose of 
treatment and is attributed (possibly, probably, or definitely) to the agent(s) must 
also be reported accordingly.  
 
Step 4:   Determine the prior experience of the adverse event.  
Expected events are those that have been previously identified as resulting from 
administration of the agent. An adverse event is considered unexpected, for 
expedited reporting purposes only, when either the type of event or the severity 
of the event is not listed in:  
• the current known adverse events listed in the Agent Information Section of 
this protocol;  
• the drug package insert;  
• the current Investigator’s Brochure  
• the study agent(s)/therapi[INVESTIGATOR_114599]  7
0 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 70 of 99   (BMS CA209 -444) V.  V6.[ADDRESS_128199] that require 
Expedited Reporting  
• Potential drug induced liver injury (DILI) is also considered an important 
medical event.  
• Suspected transmission of an infectious agent (eg, pathogenic or 
nonpathogenic) via the study drug is an SAE.  
• Although pregnancy, overdose, and cancer are not always serious by [CONTACT_8661], these events must be handled as SAEs. 
 
 
5.6 Nonserious Adverse Event Collection and Reporting 
A nonserious adverse event is an AE not classified as serious. The collection of 
nonserious AE information should begin at initiation of study drug. All nonserious adverse events (not only those deemed to be treatment- related) should be 
collected continuously during the treatment period and for a minimum of [ADDRESS_128200] dose of study treatment.  
 
Nonserious AEs should be followed to resolution or stabilization, or reported as SAEs if they become serious. Follow -up is also required for nonserious AEs that 
cause interruption or discontinuation of study drug and for those present at the end of study treatment as appropriate.
 
5.7 Handling of Expedited Safety Reports  
In accordance with local regulations, BMS and the IND Sponsor will notify investigators of all reported SAEs that are suspected (related to the investigational product) and unexpected (i.e., not previously described in the IB). Investigator notification of these events will be in the form of an expedited safety report (ESR).  
• Other important findings which may be reported by [CONTACT_114646]: increased frequency of a clinically significant expected SAE, an SAE considered associated with study procedures that could modify the conduct of the study, lack of efficacy that poses significant hazard to study subjects, clinically significant 
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  7
1 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 71 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in 
writing by [CONTACT_4530].  
 
safety finding from a nonclinical (eg, animal) study, important safety 
recommendations from a study data monitoring committee, or sponsor decision to end or  temporarily halt a clinical study for safety reasons.  
• Upon receiving an ESR from BMS, the investigator must review and retain the ESR with the IB. Where required by [CONTACT_34342] a central IRB/IEC for the study, the sponsor will submi t the ESR to the appropriate IRB/IEC. The 
investigator and IRB/IEC will determine if the informed consent requires revision. The investigator should also comply with the IRB/IEC procedures for reporting any 
other safety information.  
• In addition, suspected  serious adverse reactions (whether expected or 
unexpected) shall be reported by [CONTACT_079]  [INVESTIGATOR_114600] (either as expedited and/or in aggregate reports).  
 
5.8 Reporting: 
All AEs (both expected and unexpected) will be captured on the appropriate study -
specific CRFs.  
 
5.9 Nonserious Adverse Event 
• Nonserious Adverse Events are to be provided to BMS in aggregate via interim or final study reports as specified in the agreement or, if a regulatory requirement [e.g. IND US trial] as part of an annual reporting requirement.  
• The collection of nonserious AE information should begin at initiation of 
study drug. All nonserious adverse events (not only those deemed to be 
treatment -related) should be collected continuously during the treatment 
period and for a minimum of [ADDRESS_128201] dose of s tudy 
treatment.  
 
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  7
2 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 72 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in 
writing by [CONTACT_4530].  
 
• Nonserious AEs should be followed to resolution or stabilization, or reported 
as SAEs if they become serious. Follow -up is also required for nonserious 
AEs that cause interruption or discontinuation of study drug and for those present at the end of study treatment as appropriate.  
5.[ADDRESS_128202] Abnormalities  
• All laboratory test results captured as part of the study should be recorded following institutional procedures. Test results that constitute SAEs should be documented and reported as such.  
• The following laboratory abnormalities should be documented and reported appropriately:  
• any laboratory test result that is clinically significant or meets the definition of an SAE  
• any laboratory abnormality that required the subject to have study drug discontinued or interrupted 
• any laboratory abnormality that required the subject to receive specific corrective therapy.  
5.11 Pregnancy  
• Any pregnancy that occurs in a female partner of a male study participant should be reported to BMS. Information on this pregnancy will be collected on the Pregnancy Surveillance Form.  
5.12 Overdose  
• An overdose is defined as the accidental or intentional administration of any 
dose of a product that is considered both excessive and medically important. 
All occurrences of overdose must be reported as an SAE. 
 
 
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  7
3 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 73 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in 
writing by [CONTACT_4530].  
 
5.13 Other Safety Considerations  
• Any significant worsening noted during interim or final physical 
examinations, electrocardiograms, x rays, and any other potential safety assessments, whether or not these procedures are required by [CONTACT_760], should also be recorded as a nonserious or serious AE, as appropriate, and reported accordingly.  
5.14 Seven Calendar -Day Telephone or Fax Report:   
The IND Sponsor is required to notify the FDA of any fatal or life- threatening 
adverse event that is unexpected and assessed by [CONTACT_38241].  Such reports are to be telephoned or faxed ([PHONE_2595]) to the FDA within seven calendar days of first learning of the 
event. Follow -up information will be submitted to the FDA as soon as relevant 
information is available.  
 
5.15 15 Calendar- Day Written Report:   
The IND Sponsor is required to notify the FDA of any SAE that is unexpected and related to the investigational agent in a written IND Safety Report.   
 Written IND Safety Reports should include an Analysis of Similar Events in 
accordance with regulation 21 CFR § 312.32.  All safety reports previously filed 
with the IND concerning similar events should be analyzed.  The new report 
should contain comments on the significance of the new event in light of the previous related reports.   
 
Written IND safety reports with Analysis of Similar Events are to be submitted to the FDA within [ADDRESS_128203] learning of the event. Follow -up 
information will be submitted to the FDA as soon as relevant information is available.  
SAEs should be reported on MedWatch Form 3500A, which can be accessed at: http://www.accessdata.fda.gov/scripts/medwatch/.  
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  7
4 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 74 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in 
writing by [CONTACT_4530].  
 
 
MedWatch SA E forms should be sent to the FDA at:  
MEDWATCH  
[ADDRESS_128204]  
Rockville, MD [ZIP_CODE]- 9787 
Fax: 1- 800-FDA-0178 (1 -[PHONE_189])  
http://www.accessdata.fda.gov/scripts/medwatch/  All SAEs should simultaneously be faxed or e -mailed to BMS at:  
Global Pharmacovigilance & Epi[INVESTIGATOR_9611]- Myers Squibb Company  
Fax Number: 609- 818-3804 
Email: [EMAIL_178]
 
Following the subject’s written consent to participate in the study, all SAEs, whether related or not related to study drug, must be collected, including those thought to be 
associated with protocol -specified procedures. All SAEs must be collected that occ ur 
within [ADDRESS_128205] be collected that relate to any protocol -specified procedure (eg, a follow -up skin 
biopsy).  The investigator should report any SAE that occurs after these time periods that is believed to be related to study drug or protocol -specified procedure.  
SAEs, whether related or not related to study drug, and pregnancies must be reported to BMS within [ADDRESS_128206] be recorded on BMS or an approved form; 
pregnancies must be recorded on a Pregnancy Surveillance Form. 
SAE Email Address:  [EMAIL_176]  
SAE Facsimile Number:  609- 818-3804  
 If only limited information is initially available, follow -up reports are  required. (Note: 
Follow -up SAE reports should include the same investigator term(s) initially reported.)  
If an ongoing SAE changes in its intensity or relationship to study drug or if new information becomes available, a follow -up SAE report should be sent within 24 hours 
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  7
5 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 75 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in 
writing by [CONTACT_4530].  
 
to the BMS (or designee) using the same procedure used for transmitting the initial 
SAE report.   All SAEs should be followed to resolution or stabilization.  
The Sponsor/Investigator will ensure that all SAEs in the clinical database are reported to BMS and any applicable health authority during the conduct of the study. This reconciliation will occur at least quarterly and be initiated by [CONTACT_456]/investigator.  
 
Sponsor/investigator  will request a reconciliation report from:  
[EMAIL_177]. During reconciliation, any events found to not be 
reported previously to BMS must be sent to [EMAIL_176]. 
 6 ETHICAL CONSIDERATIONS 
 6.1 Good Clinical Practice  
This study will be conducted in accordance with Good Clinical Practice (GCP), as defined by [CONTACT_5787] (ICH) and in accordance with the ethical principles underlying European Union Directive 2001/20/EC and the [LOCATION_002] Code of Federal Regulations, Title 21, Part 50 (21CFR50).  
The study will be conducted in compliance with the protocol. The protocol and any amendments and the subject informed consent will receive Institutional Review 
Board/Independent Ethics Committee  (IRB/IEC) approval/favorable opi[INVESTIGATOR_114601].  
All potential serious breaches must be reported to Principal Investigator ([CONTACT_114663]) . A serious breach is a breach of the conditions and principles of GCP in 
connection with the study or the protocol, which is likely to affect, to a significant degree, the safety or physical or mental integrity of the subjects of the study or the scientif ic value of the study.  
Personnel involved in conducting this study will be qualified by [CONTACT_8640], training, and experience to perform their respective tasks. This study will not use the services of 
study personnel where sanctions have been invoked or where there has been scientific 
misconduct or fraud (eg, loss of medical licensure, debarment).  
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  7
6 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 76 of 99   (BMS CA209 -444) V.  V6.[ADDRESS_128207]/Independent Ethics 
Committee  
Before study initiation, the investigator must have written and dated approval/favorable 
opi[INVESTIGATOR_5698]/IEC for the protocol, consent form, subject recruitment materials 
(eg, advertisements), and any other written information to be provided to subjects. The principal investigator [INVESTIGATOR_114602]/IEC with a copy of the Investigator Broch ure or product labeling information to be provided to subjects and any updates.  
The principal investigator [INVESTIGATOR_114603]/IEC with reports, updates and other information (eg, expedited safety reports, amendments, and administrative letters) according to regulatory requirements or institution procedures.  
6.[ADDRESS_128208] volunteers to 
participate.  
The informed consent form will include all elements required by [CONTACT_114647] (ICH), Good Clinical Practice (GCP) and applicable regulatory requirements and will adhere to the ethical principles that have their origin in the Declaration of Helsinki.  
Investigators must:  
1. Provide a copy of the consent form and written information about the study in the language in which the subject is most proficient prior to clinical study participation. T he language must be non -technical and easily understood.  
2. Allow time necessary for subject or subject's legally acceptable representative to inquire about the details of the study.  
3. Obtain an informed consent signed and personally dated by [CONTACT_28246] t he 
subject's legally acceptable representative and by [CONTACT_28490].  
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  7
7 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 77 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in 
writing by [CONTACT_4530].  
 
4. Obtain the IRB/IEC’s written approval/favorable opi[INVESTIGATOR_114604], prior to the beginning of the study, and after any revisions are completed for new information.  
5. If informed consent is initially given by a subject’s legally acceptable representative or legal guardian, and the subject subsequently becomes capable of making and communicating his or her informed consent during the 
study, consent must additionally be obtained from the subject.  
6. Revise the informed consent whenever important new information becomes 
available that is relevant to the subject's consent. The investigator, or a person 
designated by [CONTACT_093], should fully inform the subject or the subject's legally acceptable representative or legal guardian, of all pertinent aspects of the study and of any new information relevant to the subject's w illingness to 
continue participation in the study. This communication should be documented.  
The confidentiality of records that could identify subjects must be protected, respecting the privacy and confidentiality rules applicable to regulatory requirements, the subjects' signed ICF and, in the US, the subjects’ signed HIPAA Authorization.  
The consent form must also include a statement that investigators and regulatory 
authorities have direct access to subject records. The rights, safety, and well -being o f 
the study subjects are the most important considerations and should prevail over 
interests of science and society.  
6.4 Multicenter Guidelines  
The Protocol Chair  
The Protocol Chair, Hans -Joerg Hammers, MD PhD, is responsible for 
performing the following Tasks: 
• Coordinating, developi[INVESTIGATOR_007], submitting, and obtaining approval for the protocol as well as its subsequent amendments  
• Assuring that all participating institutions are using the current IRB approved version of the protocol  
• Taking responsibility for the overall conduct of the study at all 
participating institutions and for monitoring the progress of the study  
• Reviewing and ensuring reporting of Serious Adverse Events (SAEs) 
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  7
8 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 78 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in 
writing by [CONTACT_4530].  
 
from all sites  
• Reviewing all study data from all sites  
 
6.5 Coordinating Center Responsibilities ( UTSW ) 
Coordinating Centers must:  
• Verify that each participating institution has a Federal Wide Assurance 
(FWA) number.  
• Confirm that IRB approval has been obtained at each participating site 
prior to their first patient registration  
• Maintai n copi[INVESTIGATOR_70695]  
• Implement central patient registration  
• Prepare all submitted data for review by [CONTACT_36476] (Hans -
Joerg Hammers, MD PhD  
• Establish procedures for documentation, reporting, and submitting of 
adverse events to the Protocol Chair (Hans -Joerg Hammers, MD 
PhD) and all applicable parties  
• Facilitate audits by [CONTACT_114648], or by [CONTACT_114649].  
 
6.6 Participating S ites Responsibilities 
Participating sites are responsible for performing the following tasks:  
6.6.[ADDRESS_128209] the study within the 
guidelines of Good Clinical Practice   
 
6.6.2 Required Documentation (for multi -site studies)  
Before the study can be initiated at any site, the following 
documentation must be provided to the Department of Urology 
{Research Office}.  
 
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  7
9 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 79 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in 
writing by [CONTACT_4530].  
 
• A copy of the official IRB approval letter for the protocol and 
informed consent  
• IRB membership list or Federal wide Assurance letter  
• CVs and medical licensure for the principal investigator [INVESTIGATOR_114605]  
• Form FDA 1572 appropriately filled out and signed with 
appropriate documentation (NOTE: this is required if {institution} 
holds the IND. Otherwise, the affiliate Investigator’s signature [CONTACT_114660])  
• A copy of the IRB -approved consent form  
• CAP and CLIA Laboratory certification numbers and institution lab normal values  
• Executed clinical research contract  
7 Data Management, Monitoring/Auditing and Reporting 
Requirements  
REDCap is the UTSW SCC institutional choice for the electronic data capture of case 
report forms for  SCC Investigator Initiated Trials. REDCap will be used for e lectronic 
case report forms in accordance with Simmons Cancer Center requirements  as 
appropriate for the projectIn order to facilitate remote source to case report form 
verification, the Simmons Comprehensive Cancer Center study team will require other 
institutions participating in this trial as sub -sites  to enter data into the selected EDC 
system  and upload selected de- identified source materials when instructed   
Trial monitoring will be conducted no less than annually and refers to a regular interval 
review of trial related activity and documentation performed by [CONTACT_114650], and/or the 
CRO Multi-Center IIT Monitor.  This review includes but is not limited to accuracy of case report forms, protocol compliance, timeless and accuracy of Velos entries and 
AE/S AE management and reporting. Documentation of trial monitoring will be 
maintained along with other protocol related documents and will be reviewed during internal audit.  
For further information, refer to the UTSW SCCC IIT Management manual. 
 Toxicity revi ews will be performed  after the first [ADDRESS_128210] been enrolled and 
then on a quarterly basis These reviews will be documented in the form of  short 
summaries after investigator discus sions. The principle investigators of all accruing  
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  8
0 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 80 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in 
writing by [CONTACT_4530].  
 
sites are required to participate.The UTSW Simmons Cancer Center (SCC) Data Safety 
Monitoring Committee (DSMC) is responsible for monitoring data quality and patient 
safety for all UTSW SCC clinical trials.  As part of that responsibility, the DSMC 
reviews all local seriou s adverse events and unanticipated problems in real time as they 
are reported and reviews adverse events on a quarterly basis.  The quality assurance 
activity for the Clinical Research Office provides for periodic auditing of clinical 
research documents to  ensure data integrity and regulatory compliance.  A copy of the 
DSMC plan is available upon request. 
 
The SCC DSMC meets quarterly and conducts annual comprehensive reviews of 
ongoing clinical trials, for which it serves as the DSMC of record. The QAC wor ks as 
part of the DSMC to conduct regular audits based on the level of risk. Audit findings are reviewed at the next available DSMC meeting.  In this way, frequency of DSMC 
monitoring is dependent upon the level of risk.  Risk level is determined by [CONTACT_114651] a number of factors such as the phase of the study; the type of investigational agent, device or intervention being studied; and monitoring required to 
ensure the safety of study subjects based on the associated risks of the study. Protocol-
specific DSMC plans must be consistent with these principles.  
[ADDRESS_128211] requires alternative treatment, the study shall 
be conducted exactly as described in the approved protocol.  
8.2 Emergency Exceptions (also called single-subject 
exceptions or single- subject waivers)  
These include any departure from IRB -approved research that is not due to an emergency  
and is:  
• intentional on part of the investigator; or  
• in the investigator’s control; or  
• not intended as a  systemic change (e.g., single- subject 
exceptions to eligibility  [inclusion/exclusion] criteria)  
 Reporting requirement: Exceptions are non- emergency deviations that require 
prospective  IRB approval before being implemented. Call the 
IRB if your request is urgent. If IRB approval is not obtained 
beforehand, this constitutes a major deviation.  
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  8
1 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 81 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in 
writing by [CONTACT_4530].  
 
Emergency Deviations: include any departure from IRB- approved research that is 
necessary to:  
• avoid immediate apparent harm, or  
• protect the life or physical well -being of subjects or others  
 Reporting requirement : Emergency deviations must be promptly reported 
to the IRB within (5) working days of the occurrence.  
 
8.3  Major  Deviations/ (also called violations):  include 
any departure from IRB -approved research that:  
● Harmed or placed subjects(s) or others at risk of harm (  e., did or has the potential 
to negatively affect the safety, rights or welfare of subjects or 
others), or  
● Affe ct data quality (e.g., the completeness, accuracy,  reliability, o validity  of the 
data) or the science of the research ( e.g., the primary 
outcome/endpoint of the study)  
 Reporting requirement: Major deviations must be promptly reported to the IRB within 
5 working days of PI [INVESTIGATOR_38417].  
 
8.3.1  Minor Deviations:  include any departure from the IRB approved research that:  
       ● Did not harm or place subjects(s) or others at risk of harm (i.e., did not or did not 
have the potential to negatively affect the safety, rights, or welfare of subjects or 
others), or  
 ●  Did not affect data quality (e.g., the completeness, accuracy, reliability, or validity 
of the data) or the science of the research (e.g., the primary outcome/endpoint of the 
study)  
 Reporting requirement : Major deviations must be promptly reported to the IRB within 5 
working days of PI [INVESTIGATOR_38417].  
• Harmed or placed subject(s)  or Others  at risk of harm (i.e., did or 
has the potential to negatively  affect the safety, rights,  or welfare 
of subjects or others), or  
• Affect data quality (e.g., the completeness, accuracy, reliability, or 
validity of the data) or the science of the research (e.g., the 
primary outcome/endpoint of the study)  
 Reporting requirement: Major deviations must be promptly 
reported to  
the IRB within 5 working days of PI [INVESTIGATOR_38417].  
8.4  Amendments to the Protocol  
Should amendments to the protocol be required, the amendments will be originated and 
documented by [CONTACT_079].  A summary of changes document outlining 
proposed changes as well as rationale for changes, when appropriate, is highly 
recommended.  When an amendment to the protocol substantially alters the study 
design or the potential risk to the patient, a revised consent form might be required.  
 
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  8
2 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 82 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in 
writing by [CONTACT_4530].  
 
8.5 Case Report Form Submission  
Data required by [CONTACT_114652] (SKCCC). The participating site will be required to complete a paper Eligibility Checklist case report form (CRF) at the time of patient registration.  All other data will be collected on the electronic case report forms (eCRFs) in CRMS. Site staff access to CRMS will be initiated at the time of the site activation.  
 
8.5.1 Case Report Forms  
Case report forms (e -CRF) will be generated by [CONTACT_114653]. Investigators will be responsible 
for ensuring that the CRFs are kept up- to-date.  
 8.5.[ADDRESS_128212] 
be crossed out so that the original entry is still visible, the correction clearly indicated and then initialed and dated by [CONTACT_114654].  
 eCRFs( REDCAP) will be completed within 2 weeks of the patient coming to the clinic 
and all relevant supporting documentation such as scans, progress notes, nursing notes, blood work, pathology reports, etc., will be submitted to the Coordinating Center 
(UTSW ) via e mail at  [EMAIL_2255] to the Lead Center Program 
Coordinator,  Allison Beaver. All patient names or other identifying information will be 
removed prior to being sent to the Coordinating Center ( UTSW ) or non - redacted 
source documents can be sent via a password ¬ -protected/ secured document transfer 
based on each institution’s guidelines.  
 
Authorized representatives of the Coordinating Center ( UTSW ) may be performing 
audits or inspections, including source data verification. The purpose of these audits or inspections is to systematically and independently examine all trial -related activities 
and documents to determine whether these activities were conducted and data were recorded, analyzed, and accurately reported according to the protocol, Good Clinical Practice (GCP), and any applicable regulatory requirements.  
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  8
3 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 83 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in 
writing by [CONTACT_4530].  
 
9 Statistical Considerations 
 9.1 Study Design  
This is a multi- institution, open- label, single -arm Phase II study to determine the safety 
and efficacy of SBRT followed by [CONTACT_114655][INVESTIGATOR_114606]. The primary endpoints of safety evaluated by [CONTACT_114656] G3/[ADDRESS_128213] criteria. Secondary endpoints include TTP, 
DOR, PFS, OS and local control of irradiated lesion. Simon’s minimax two- stage 
design will be used to allow for early termination of the study if addition of SBRT to nivolumab in combination with ipi[INVESTIGATOR_114607]. A safety run- in 
phase will be included in the first [ADDRESS_128214] six patients enrolled will be treated with a combination regimen cons isting in 
nivolumab 3 mg/kg IV combined with ipi[INVESTIGATOR_125] 1 mg/kg IV and SBRT within [ADDRESS_128215] 6 patients experience Grade 3/4 toxicity during the safety run -in observation period 
(defined as the first 4-cycles, 12 weeks), enrollment will cease and the study will be 
halted until further safety analysis of the combination regimen can be performed. If less than [ADDRESS_128216] 6 patients experience Grade 3/4 toxicities  or require steroids , we 
will proceed with additional accrual with this regimen to complete a total of 15 patients for Stage 1 interim analysis.  
9.3  Justification for the Sample Size  
The point estimate of the ORR with nivolumab in combination with ipi[INVESTIGATOR_114608] 40%, based on the Phase I presented at ASCO meeting which is chosen as the reference rate (P0) in the study proposed. The response rate where the regimen would be considered promising to pursue further is 70% (P1). In the first stage, 
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  8
4 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 84 of 99   (BMS CA209 -444) V.  V6.[ADDRESS_128217] a 90%  chance (power) of 
concluding the combination therapy is effective when the true response rate is 70% and a 5% chance (Type I error) of concluding the treatment is effective when the true response rate is 40% or less. The probability of stoppi[INVESTIGATOR_30492] 61% if the true response rate is 40% or less and 1.5% if the true response rate is 70%. The null 
hypothesis will be rejected and the regimen will be declared a success if at the end of 
the study 17 or more responses are observed in 25 treated subjects. The anticipated 
accrual rate for this group of patients is expected to be 2 patients per month.  
 
Early Stoppi[INVESTIGATOR_114609]: The safety profile of the combination of SBRT 
with dual immune checkpoint inhibition using nivolumab and ipi[INVESTIGATOR_114610], and therefore we will conduct continuous toxicity monitoring after safety run-in to ensure this combination is safe. If the risk of Grade 3/4 adverse events 
convincingly exceeds 50%, a threshold we are comfortable given the potential benef it 
of the regimen as well as our experience in managing the side effects in this patient population, we will temporarily halt the study and carefully review  the available data at 
that point in order to suggest potential modification of the combination regimen. 
Specifically, a Bayesian toxicity monitoring rule will suggest suspending enrollment if the posterior probability of risk being larger than 0.50 is 75% or higher. The prior for this monitoring rule is beta (1, 2), representing the risk of DLT has mean of 33% and 
there is 90% probability that this risk is between 2.5% and 78%. The stoppi[INVESTIGATOR_114611] 5000 simulations are as below.  
 
 
    
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  8
5 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 85 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in 
writing by [CONTACT_4530].  
 
No. patients 
experiencing G3/4 
AE/steroid needs  6 7 8 9 10 11 12 13 14 15 
Out of  7-8 9-10 11-12 13-14 15-16 17 18-19 20-21 22-23 24-25 
 
True risk of AE  Prob. declaring regimen too toxic  Avg. sample size  
0.30 2.1%  24.7 
0.40 12.8%  23.3 
0.50 38.5%  20.1 
0.60 71.3%  15.6 
0.65 85.3%  13.2 
0.70 94.6%  10.[ADDRESS_128218] one does of study medication. The ORR will be estimated as the proportion of subjects who achieve a response (CR/PR) assessed by [CONTACT_393]. The corresponding two- sided 95% exact 
confidence interval will be calculated assuming a binomial distr ibution. The efficacy 
evaluable population includes all subjects who receive at least one dose of study drug, 
have an adequate baseline disease assessment and at least one post -baseline 
response assessment.  
 9.5 Statistical Analyses of Secondary Endpoints 
Clinical Endpoints: Time -to-event outcomes (e.g., TTP, DOR, PFS, OS, local 
control of irradiated lesion) will be described using the Kaplan- Meier method. 
Median values will also be estimated with 95% confidence intervals.  
 
Exploratory Correlative studies: Optional biopsies will be performed in all subjects 
at baseline (within 28 days prior to combination therapy) and during week [ADDRESS_128219] -therapy will be 
summarized with descriptive statistics and graphically displayed by [CONTACT_114657].     Frequencies and percentages will be presented for categorical variables. Changes will be estimated as a ratio change (post/pre) and data will be log transformed as appropriate to induce symmetry and stabilize the variability. 
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  8
6 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 86 of 99   (BMS CA209 -444) V.  V6.[ADDRESS_128220] -therapy will be explored using paired t- tests or 
nonparametric Wilcoxon signed rank tests for continuous variables and McNemar’s 
test for dichotomous or categorical variables (e.g., proportion of subjects with marke r-positive at pre - and post -therapy). Distributions of immune parameters 
across clinical responders and non -responders will be evaluated and graphically 
displayed using box plots. Differences of baseline and change in these parameters across tumor response groups will be explored using Jonckheere -Terpstra trend 
test, Wilcoxon rank sum test as well as logistic regression where appropriate.  
[ADDRESS_128221] Retention  
Study documentation includes all Case Report Forms, data correction forms or 
queries, source documents, Sponsor -Investigator correspondence, monitoring 
logs/letters, and regulatory documents (e.g., protocol and amendments, IRB 
correspondence and approval, signed patient consent forms).  
 Source documents include all recordings of observations or no tations of clinical 
activities and all reports and records necessary for the evaluation and reconstruction of the clinical research study.  
 Government agency regulations and directives require that the study investigator 
retain all study documentation pertaining to the conduct of a clinical trial. In the case 
of a study with a drug seeking regulatory approval and marketing, these documents shall be retained for at least two years after the last approval of marketing application in an International Conference on Harmonization (ICH) region. In all other cases, study documents should be kept on file until three years after the completion and final study report of this investigational study.  
   
 
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  8
7 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 87 of 99   (BMS CA209 -444) V.  V6.[ADDRESS_128222] of the clinical trial at the site 
in accordance with Title 21 of the Code of Federal Regulations and/or the Declaration of Helsinki. The Principal Investigator [INVESTIGATOR_39686]. The Principal Investigator [INVESTIGATOR_9979], including sub -investigators and other study staff members, adhere to the 
study protocol and all FDA/GCP/NCI regulations and guidelines regarding clinical trials both during and afte r study completion.  
 The Principal Investigator [INVESTIGATOR_114612]. 
Periodically, monitoring visits may be conducted and the Princ ipal Investigator will 
provide access to his/her original records to permit verification of proper entry of data. At the completion of the study, all case report forms will be reviewed by [CONTACT_079] [INVESTIGATOR_44302]/her final signature [CONTACT_10015].  
    
 
        
 
 
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  8
8 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 88 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in 
writing by [CONTACT_4530].  
 
12 REFERENCES 
 1. Cancer Facts and Figures. American Cancer Society. Atlanta: American Cancer 
Society;, 2010 
 2. Cancer of the Kidney: Section 3. W. Marston Linehan BIR, James C. Yang, in 
Cancer.: Principles & Practice Oncology / edited by [CONTACT_85006] T. DeVita, SAmuel Hellman, Steven A. Rosenberg. Philadelphia: Lipi[INVESTIGATOR_10354] -Raven; 8th edition  
 3. Motzer RJ, Bacik J, Mazum dar M: Prognostic factors for survival of patients 
with stage IV renal cell carcinoma: memorial sloan -kettering cancer center experience. Clin 
Cancer Res 10:6302S -3S, 2004 
 4. Heng DY, Xie W, Regan MM, et al: Prognostic factors for overall survival in 
patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-
targeted agents: results from a large, multicenter study. J Clin Oncol 27:5794 -9, 2009 
 5. Fyfe G, Fisher RI, Rosenberg SA, et al: Results of treatment of 255 patient s 
with metastatic renal cell carcinoma who received high -dose recombinant interleukin -2 
therapy. J Clin Oncol 13:688 -96, 1995 
 6. Negrier S, Escudier B, Lasset C, et al: Recombinant human interleukin -2, 
recombinant human interferon alfa- 2a, or both in meta static renal- cell carcinoma. Groupe 
Francais d'Immunotherapie. N Engl J Med 338:1272 -8, 1998 
 7. Aldesleukin (IL -2) US Prescribing Information. April 2010.  
 8. McDermott DF, Regan MM, Clark JI, et al: Randomized phase III trial of high -
dose interleukin -2 versus subcutaneous interleukin- 2 and interferon in patients with 
metastatic renal cell carcinoma. J Clin Oncol 23:133 -41, 2005 
 9. Coppin C, Porzsolt F, Awa A, et al: Immunotherapy for advanced renal cell 
cancer. Cochrane Database Syst Rev:CD001425, 2005  
 10. Motzer RJ, Hutson TE, Cella D, et al: Pazopanib versus sunitinib in metastatic 
renal- cell carcinoma. N Engl J Med 369:722 -31, 2013  
 11. Escudier B, Pluzanska A, Koralewski P, et al: Bevacizumab plus interferon alfa-
2a for treatment of metastatic renal cell carcinoma: a randomised, double -blind phase III trial. 
Lancet 370:2103 -11, 2007  
 12. Hudes G, Carducci M, Tomczak P, et al: Temsirolimus, interferon alfa, or both 
for advanced renal-cell carcinoma. N Engl J Med 356:[ADDRESS_128223] S, et al: Efficacy of everolimus in advanced 
renal cell carcinoma: a double -blind, randomised, placebo -controlled phase III trial. Lancet 
372:449 -56, 2008  
 14. Motzer RJ, Rini BI, McDermott DF, et al: Nivolumab for Metastatic Renal Cell 
Carcin oma: Results of a Randomized Phase II Trial. J Clin Oncol 33:1430 -7, 2015 
 15. https://clinicaltrials.gov/ct2/show/[STUDY_ID_REMOVED]
.  
 16. Yang JC, Hughes M, Kammula U, et al: Ipi[INVESTIGATOR_125] (anti- CTLA 4 antibody) 
causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 30:825 -30, 2007  
 17. Hans J. Hammers ERP, Jeffrey R. Infante, Marc S. Ernstoff, Brian I. Rini, David 
F. McDermott, Albiruni R. A. Razak, Sumanta Kumar Pal, Martin Henner Voss, Padmanee Sharma, Christian K. Kollmannsberger, Daniel Yick Chin Heng, Jennifer L. Spratlin, Yun Shen, John F. Kurland, Paul Gagnier, Asim Amin,: Phase I study of nivolumab in combination with ipi[INVESTIGATOR_114613] (mRCC). J Clin Oncol 32:5S, 2014  
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  8
9 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 89 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in 
writing by [CONTACT_4530].  
 
 18. Hans J. Hammers ERP, Jeffrey R. Infante, Brian I. Rini, David F. McDermott, 
Marc Ernstoff, Martin Henner Voss, Padmanee Sharma, Sumanta Kumar Pal, Albiruni R. A. 
Razak, Christian K. Kollmannsberger, Daniel Yick Chin Heng, Jennifer L. Spratlin, Yun Shen, Paul Gagnier, Asim Amin.: Expanded cohort results from CheckMate 016: A phase I study of nivolumab in combination with ipi[INVESTIGATOR_114613] (mRCC). J Clin Oncol 33, 2015  
 19. Tinkle CL SS, Weinberg VK, et al. : Comparison of stereotactic body 
radiotherapy (SBRT) and conventional external beam radiotherapy (EBRT) in renal cell carcinoma (RCC).  . Oncology (Williston Park)  21;29([ADDRESS_128224] 1), 2015  
 20. Siva S, Pham D, Gill S, et al: A systematic review of stereotactic radiotherapy 
ablation for primary renal cell carcinoma. BJU Int 110:E737 -43, 2012  
 21. Lee Y, Auh SL, Wang Y, et al: Therapeutic effects of ablative radiation on local 
tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 114:589 -95, 2009  
 22. Lugade AA, Moran JP, Gerber SA, et al: Local radiation therapy of B16 
melanoma tumors increases the generation of tumor antigen -specific effector cells that traffic 
to the tumor. J Immunol 174:[ADDRESS_128225] AE, Kawashima N, et al: Fractionated but not single -dose 
radiotherapy induces an immune -mediated abscopal effect when combined with anti -CTLA -4 
antibody. Clin Cancer Res 15:5379 -88, 2009  
 24. Schaue D, Ratikan JA, Iwamoto KS, et al : Maximizing tumor immunity with 
fractionated radiation. Int J Radiat Oncol Biol Phys 83:1306 -10, 2012  
 25. Postow MA, Callahan MK, Barker CA, et al: Immunologic correlates of the 
abscopal effect in a patient with melanoma. N Engl J Med 366:925 -31, 2012  
 2 6. Hiniker SM, Chen DS, Reddy S, et al: A systemic complete response of 
metastatic melanoma to local radiation and immunotherapy. Transl Oncol 5:404 -7, 2012 
 27. Kong FM, Ritter T, Quint DJ, et al: Consideration of dose limits for organs at 
risk of thoracic radiotherapy: atlas for lung, proximal bronchial tree, esophagus, spi[INVESTIGATOR_1831], ribs, and brachial plexus. Int J Radiat Oncol Biol Phys 81:[ADDRESS_128226] S YK, Followill D, et al.  : Stereotactic body radiation therapy: the 
report of AAPM Tas k Group 101.  . Med Phys 37(8);:4078- 101 
 29. Fernando HC, Timmerman R: American College of Surgeons Oncology Group 
Z4099/Radiation Therapy Oncology Group 1021: a randomized study of sublobar resection compared with stereotactic body radiotherapy for high -risk stage I non -small cell lung cancer. 
J Thorac Cardiovasc Surg 144:S35 -8, 2012 
 30. Shahabi V, Postow MA, Tuck D, et al: Immune -priming of the tumor 
microenvironment by [CONTACT_114658]: rationale for combination with immunotherapy to improve anticancer efficacy. Am J Clin Oncol 38:90 -7, 2015  
 31. Seung SK, Curti BD, Crittenden M, et al: Phase 1 study of stereotactic body 
radiotherapy and interleukin -2--tumor and immunological responses. Sci Transl Med 
4:137ra74, 2012  
 32. Redman BG, Hillman GG, Flaherty L, et al: Phase II trial of sequential radiation 
and interleukin 2 in the treatment of patients with metastatic renal cell carcinoma. Clin Cancer Res 4:283 -6, 1998 
 33. Sharabi AB, Nirschl CJ, Kochel CM, et al: Stereotactic Radiation Therapy 
Augments Antigen -Specific PD -1-Mediated Antitumor Immune Responses via Cross -
Presentation of Tumor Antigen. Cancer Immunol Res 3:345 -55, 2015  
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  9
0 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 90 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in 
writing by [CONTACT_4530].  
 
 34. Twyman -Saint Victor C, Rech AJ, Maity A, et al: Radiation and dual checkpoint 
blockade activate non -redundant immune mechanism s in cancer. Nature 520:[ADDRESS_128227] Joseph Appleman, Lawrence Fong, Charles G. 
Drake, Lewis J. Cohen, Shivani Srivastava, Maria Jure -Kunkel, Quan Hong, John F. Kurland, 
Mario Sznol: Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mR CC): Biomarker- based results from a randomized clinical 
trial. J Clin Oncol 32:5s, [ADDRESS_128228] Joseph Appleman, Lawrence Fong, Charles G. Drake, Tina C. Young, Scott D. Chasalow, Petra Ross -Macdonald, Jason S. Simon, 
Dana Walker and Mario Sznol: Immunomodulatory activity of nivolumab in previous ly treated 
and untreated metastatic renal cell carcinoma (mRCC): Biomarker- based results from a 
randomized clinical trial. Journal of Clinical Oncology 33, 2015 
 
  
 
        
 
   
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  9
1 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 91 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in 
writing by [CONTACT_4530].  
 
13 APPENDIX 1          INTERNATIONAL METASTATIC 
RCC DATABASE CONSORTIUM (IMDC) PROGNOSTIC 
CRITERIA 
Adverse Prognostic Factors  
Clinical  
KPS < 80%  
Time from diagnosis to treatment < 1 year  
Laboratory  
Hemoglobin < LLN  
Corrected calcium > ULN  
Absolute neutrophil count > ULN  
Platelet count > ULN  
  LLN = Lower limit of normal    
  ULN = Upper limit of normal  
 
  Corrected calcium (mg/dL) = measured total Ca (mg/dL) + 0.8 (4.0 - serum  albumin[g/dL]),       
where 4.0 represents the average albumin level in g/dL.  
  Corrected calcium (mmol/L) = measured total Ca (mmol/L) + 0.02 (40 - serum  albumin[g/L]), 
where 40 represents the average albumin level in g/L  
 
Risk Group Based on Number of Adverse Prognostic Factors  
Number of Adverse Prognostic Factors 
Present  Risk Group  
0 Favorable  
1-2 Intermediate  
3-6 Poor  
 
     
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  9
2 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 92 of 99   (BMS CA209 -444) V.  V6.[ADDRESS_128229], especially prior to an invasive diagnostic or therapeutic procedure, is recommended.  
The freq uency and severity of the related adverse events covered by [CONTACT_114659]- oncology agent or regimen being used.  
     
 
    
 
        
 
  
SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  9
3 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 93 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in writing by [CONTACT_4530].  
 
 

SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  9
4 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 94 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in writing by [CONTACT_4530].  
 
 

SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  9
5 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 95 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in writing by [CONTACT_4530].  
 
 

SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  9
6 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 96 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in writing by [CONTACT_4530].  
 
 

SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  9
7 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 97 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in writing by [CONTACT_4530].  
 
 

SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  9
8 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 98 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in writing by [CONTACT_4530].  
 
 

SBRT in combination with nivolumab and ipi[INVESTIGATOR_125]  9
9 
 
 
STU072016 -044, Hammers, FormA -ResearchProtocol- V7.0- 09.30.19, Mod_14, 10 -23-19 (2)       
Page 99 of 99   (BMS CA209 -444) V.  V6.0 date March 1, 2019  
This material is the property of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in writing by [CONTACT_4530].  
 
 
